Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,500 | 2020-06-25 00:00:00 UTC | Sosei, AbbVie sign drug discovery deal worth up to $1 bln | ABBV | https://www.nasdaq.com/articles/sosei-abbvie-sign-drug-discovery-deal-worth-up-to-%241-bln-2020-06-25 | null | null | Updates size of deal, adds spokesman
June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with AbbVie Inc ABBV.N on a drug discovery partnership that could be worth up to $1 billion.
Sosei shares soared 12.4% in Tokyo trading, compared with a 1.2% slide in the broader market.
The partnership will initia... | Updates size of deal, adds spokesman June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with AbbVie Inc ABBV.N on a drug discovery partnership that could be worth up to $1 billion. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. The partnership will initiall... | Updates size of deal, adds spokesman June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with AbbVie Inc ABBV.N on a drug discovery partnership that could be worth up to $1 billion. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. An expansion to four targets ... | Updates size of deal, adds spokesman June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with AbbVie Inc ABBV.N on a drug discovery partnership that could be worth up to $1 billion. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. An expansion to four targets ... | Updates size of deal, adds spokesman June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with AbbVie Inc ABBV.N on a drug discovery partnership that could be worth up to $1 billion. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. Sosei shares soared 12.4% in ... |
24,501 | 2020-06-24 00:00:00 UTC | Japan's Sosei Group signs $377 mln drug discovery deal with Abbvie | ABBV | https://www.nasdaq.com/articles/japans-sosei-group-signs-%24377-mln-drug-discovery-deal-with-abbvie-2020-06-24 | null | null | June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday.
Sosei shares climbed 10% in Tokyo trading, compared with a 1% slide in the broader market.
The partnership will initially focus on the discove... | June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. The partnership will initially focus on the discov... | June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. Sosei shares climbed 10% in Tokyo trading, compare... | June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. Sosei is eligible to receive up to $32 million in ... | June 24 (Reuters) - Japan's Sosei Group Corp 4565.T will collaborate with Abbvie Inc ABBV.N on drug discovery in a deal worth up to $377 million, the companies said on Thursday. Chicago-based AbbVie has the option to expand the collaboration to a total of four targets. Sosei shares climbed 10% in Tokyo trading, compare... |
24,502 | 2020-06-23 00:00:00 UTC | 3 Stocks You Can Keep Forever | ABBV | https://www.nasdaq.com/articles/3-stocks-you-can-keep-forever-2020-06-23 | null | null | Warren Buffett has said the best time to sell is never, and though he often doesn't follow his own rules -- as the recent sale of all the airline stocks in his portfolio attests -- it remains a good guide for investors nonetheless.
Finding good companies to invest in at the beginning means we can hold onto them for a l... | AbbVie Two factors have typically informed an investor's decision to buy pharmaceutical giant AbbVie (NYSE: ABBV): its healthy dividend and its arthritis treatment Humira, one of the best-selling drugs of the past two decades. The annual dividend of $4.72 per share yields 4.9% and remains as safe as ever -- even during... | AbbVie Two factors have typically informed an investor's decision to buy pharmaceutical giant AbbVie (NYSE: ABBV): its healthy dividend and its arthritis treatment Humira, one of the best-selling drugs of the past two decades. The annual dividend of $4.72 per share yields 4.9% and remains as safe as ever -- even during... | AbbVie Two factors have typically informed an investor's decision to buy pharmaceutical giant AbbVie (NYSE: ABBV): its healthy dividend and its arthritis treatment Humira, one of the best-selling drugs of the past two decades. The annual dividend of $4.72 per share yields 4.9% and remains as safe as ever -- even during... | AbbVie Two factors have typically informed an investor's decision to buy pharmaceutical giant AbbVie (NYSE: ABBV): its healthy dividend and its arthritis treatment Humira, one of the best-selling drugs of the past two decades. The annual dividend of $4.72 per share yields 4.9% and remains as safe as ever -- even during... |
24,503 | 2020-06-23 00:00:00 UTC | AbbVie Says FDA To Review SNDA For IMBRUVICA In Combination With Rituximab - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-says-fda-to-review-snda-for-imbruvica-in-combination-with-rituximab-quick-facts | null | null | (RTTNews) - Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type o... | (RTTNews) - Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type o... | (RTTNews) - Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type o... | (RTTNews) - Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type o... | (RTTNews) - Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type o... |
24,504 | 2020-06-23 00:00:00 UTC | Meet the Pharma Company That Just Had a Bigger IPO Than Moderna's | ABBV | https://www.nasdaq.com/articles/meet-the-pharma-company-that-just-had-a-bigger-ipo-than-modernas-2020-06-23 | null | null | Moderna (NASDAQ: MRNA) set the record for the biggest initial public offering (IPO) in biotech history on Dec. 6, 2018. The biotech raised over $600 million. But while Moderna's IPO was the biggest ever for a biotech, it wasn't the biggest one in the biopharmaceutical industry. That honor belongs to animal health compa... | 1 top-seller for AbbVie. It owns royalties to a long list of other successful products, including Biogen's multiple sclerosis drugs Tecfidera and Tysabri, Merck's diabetes drugs Januvia and Janumet, Pfizer's cancer drugs Ibrance and Xtandi, and Imbruvica, the blockbuster cancer drug marketed by AbbVie and J&J. See the ... | It owns royalties to a long list of other successful products, including Biogen's multiple sclerosis drugs Tecfidera and Tysabri, Merck's diabetes drugs Januvia and Janumet, Pfizer's cancer drugs Ibrance and Xtandi, and Imbruvica, the blockbuster cancer drug marketed by AbbVie and J&J. See the 10 stocks *Stock Advisor ... | 1 top-seller for AbbVie. It owns royalties to a long list of other successful products, including Biogen's multiple sclerosis drugs Tecfidera and Tysabri, Merck's diabetes drugs Januvia and Janumet, Pfizer's cancer drugs Ibrance and Xtandi, and Imbruvica, the blockbuster cancer drug marketed by AbbVie and J&J. See the ... | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Gilead Sciences, Pfizer, and Vertex Pharmaceuticals. 1 top-seller for AbbVie. It owns royalties to a long list of other successful products, including Biogen's multiple sclerosis drugs Tecfidera and Tysabri, Merck's diabet... |
24,505 | 2020-06-22 00:00:00 UTC | Allergan Files SBLA To Extend Use Of BOTOX For Patients 5 To 17 Years Old | ABBV | https://www.nasdaq.com/articles/allergan-files-sbla-to-extend-use-of-botox-for-patients-5-to-17-years-old-2020-06-22 | null | null | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced the U.S. FDA has accepted the company's supplemental biologics license application to expand the BOTOX prescribing information for the treatment of signs and symptoms of detrusor overactivity associated with an underlying neurologic condition in pediatric patien... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced the U.S. FDA has accepted the company's supplemental biologics license application to expand the BOTOX prescribing information for the treatment of signs and symptoms of detrusor overactivity associated with an underlying neurologic condition in pediatric patien... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced the U.S. FDA has accepted the company's supplemental biologics license application to expand the BOTOX prescribing information for the treatment of signs and symptoms of detrusor overactivity associated with an underlying neurologic condition in pediatric patien... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced the U.S. FDA has accepted the company's supplemental biologics license application to expand the BOTOX prescribing information for the treatment of signs and symptoms of detrusor overactivity associated with an underlying neurologic condition in pediatric patien... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced the U.S. FDA has accepted the company's supplemental biologics license application to expand the BOTOX prescribing information for the treatment of signs and symptoms of detrusor overactivity associated with an underlying neurologic condition in pediatric patien... |
24,506 | 2020-06-19 00:00:00 UTC | FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars | ABBV | https://www.nasdaq.com/articles/fda-nod-for-epzm-rare-court-rules-in-myls-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars | null | null | (RTTNews) - Today's Daily Dose brings you news about Alpine Immune's deal with AbbVie; FDA approval of Epizyme's TAZVERIK and Ultragenyx Pharma's Crysvita for new indications; reverse merger between privately-held Ocuphire Pharma and Rexahn Pharma and Court ruling in Biogen's Tecfidera patent suit.
Read on…
1. Alpine S... | (RTTNews) - Today's Daily Dose brings you news about Alpine Immune's deal with AbbVie; FDA approval of Epizyme's TAZVERIK and Ultragenyx Pharma's Crysvita for new indications; reverse merger between privately-held Ocuphire Pharma and Rexahn Pharma and Court ruling in Biogen's Tecfidera patent suit. Alpine Soars On AbbV... | (RTTNews) - Today's Daily Dose brings you news about Alpine Immune's deal with AbbVie; FDA approval of Epizyme's TAZVERIK and Ultragenyx Pharma's Crysvita for new indications; reverse merger between privately-held Ocuphire Pharma and Rexahn Pharma and Court ruling in Biogen's Tecfidera patent suit. Alpine Soars On AbbV... | (RTTNews) - Today's Daily Dose brings you news about Alpine Immune's deal with AbbVie; FDA approval of Epizyme's TAZVERIK and Ultragenyx Pharma's Crysvita for new indications; reverse merger between privately-held Ocuphire Pharma and Rexahn Pharma and Court ruling in Biogen's Tecfidera patent suit. Alpine Soars On AbbV... | (RTTNews) - Today's Daily Dose brings you news about Alpine Immune's deal with AbbVie; FDA approval of Epizyme's TAZVERIK and Ultragenyx Pharma's Crysvita for new indications; reverse merger between privately-held Ocuphire Pharma and Rexahn Pharma and Court ruling in Biogen's Tecfidera patent suit. Alpine Soars On AbbV... |
24,507 | 2020-06-18 00:00:00 UTC | Stock Alert: Alpine Immune Jumps 100% After Inking Deal With AbbVie | ABBV | https://www.nasdaq.com/articles/stock-alert%3A-alpine-immune-jumps-100-after-inking-deal-with-abbvie-2020-06-18 | null | null | (RTTNews) - Shares of Alpine Immune Sciences, Inc. (ALPN) more-than-doubled on Thursday morning. The company signed a deal with AbbVie Inc. (ABBV) for the development and commercialization of ALPN-101.
ALPN is currently trading at $10.01, up $5.14 or 105.54%, on the Nasdaq. Alpine Immune Sciences has granted AbbVie opt... | Alpine Immune Sciences has granted AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, as part of AbbVie's efforts to develop novel therapies in Immunology. The company signed a deal with AbbVie Inc. (ABBV) for the development and commercializa... | Alpine Immune Sciences has granted AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, as part of AbbVie's efforts to develop novel therapies in Immunology. The company signed a deal with AbbVie Inc. (ABBV) for the development and commercializa... | Alpine Immune Sciences has granted AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, as part of AbbVie's efforts to develop novel therapies in Immunology. The company signed a deal with AbbVie Inc. (ABBV) for the development and commercializa... | Alpine Immune Sciences has granted AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, as part of AbbVie's efforts to develop novel therapies in Immunology. The company signed a deal with AbbVie Inc. (ABBV) for the development and commercializa... |
24,508 | 2020-06-18 00:00:00 UTC | Alpine Immune, AbbVie Enter Into Option And License Deal For ALPN-101 | ABBV | https://www.nasdaq.com/articles/alpine-immune-abbvie-enter-into-option-and-license-deal-for-alpn-101-2020-06-18 | null | null | (RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, and biopharmaceutical company AbbVie Inc. (ABBV), said Thursday they have entered into an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.
Alpine Immune is foc... | (RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, and biopharmaceutical company AbbVie Inc. (ABBV), said Thursday they have entered into an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. Upon exercise of the... | In exchange, AbbVie will receive an option to an exclusive license for ALPN-101. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101. (RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, and bio... | (RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, and biopharmaceutical company AbbVie Inc. (ABBV), said Thursday they have entered into an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. In exchange, AbbVie ... | In exchange, AbbVie will receive an option to an exclusive license for ALPN-101. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101. (RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, and bio... |
24,509 | 2020-06-18 00:00:00 UTC | AbbVie's Rinvoq Shows Improvement In Skin Clearance And Itch In Phase 3 Study For Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvies-rinvoq-shows-improvement-in-skin-clearance-and-itch-in-phase-3-study-for-atopic | null | null | (RTTNews) - AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis.
The results from a Phase 3 study evaluating Rinvoq in moderate to severe atopic dermatitis in adults and adolescents showed both doses of upadacitinib (15 mg ... | (RTTNews) - AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. Rinvoq, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily oral therapy for moderate to severe atop... | (RTTNews) - AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. Rinvoq, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily oral therapy for moderate to severe atop... | (RTTNews) - AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. Rinvoq, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily oral therapy for moderate to severe atop... | (RTTNews) - AbbVie (ABBV) said that Rinvoq or upadacitinib monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis. Rinvoq, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily oral therapy for moderate to severe atop... |
24,510 | 2020-06-17 00:00:00 UTC | Daily Dividend Report: ORCL,MA,ABBV,TOL,USB | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-orclmaabbvtolusb-2020-06-17 | null | null | The Oracle board of directors declared a quarterly cash dividend of $0.24 per share of outstanding common stock. This dividend will be paid to stockholders of record as of the close of business on July 15, 2020, with a payment date of July 28, 2020.
The Mastercard Board of Directors declared a quarterly cash dividend o... | The cash dividend will be paid on August 7, 2020 to holders of record of its Class A common stock and Class B common stock as of July 9, 2020 The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 perc... | The cash dividend will be paid on August 7, 2020 to holders of record of its Class A common stock and Class B common stock as of July 9, 2020 The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 perc... | The cash dividend will be paid on August 7, 2020 to holders of record of its Class A common stock and Class B common stock as of July 9, 2020 The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 perc... | The cash dividend will be paid on August 7, 2020 to holders of record of its Class A common stock and Class B common stock as of July 9, 2020 The board of directors of AbbVie today declared a quarterly cash dividend of $1.18 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 195 perc... |
24,511 | 2020-06-13 00:00:00 UTC | Where Will AbbVie Be in 5 Years? | ABBV | https://www.nasdaq.com/articles/where-will-abbvie-be-in-5-years-2020-06-13 | null | null | American biopharma AbbVie (NYSE: ABBV) is renowned for its blockbuster drug, Humira, which was one of the best-selling drugs of the last 20 years. Since its 2013 separation from Abbott Laboratories (NYSE: ABT), AbbVie's stock has grown more than 160%. And with a dividend yield of 4.9%, AbbVie is quite attractive for in... | This means that despite eating some of Gilead Sciences' (NASDAQ: GILD) market share for hepatitis C therapeutics in the lead-up to Solvaldi's revenues collapsing in 2017, AbbVie cannot assume that Mavyret will not meet the same unprofitable fate, especially as its sales started to fall in 2018 and then fell sharply by ... | This means that despite eating some of Gilead Sciences' (NASDAQ: GILD) market share for hepatitis C therapeutics in the lead-up to Solvaldi's revenues collapsing in 2017, AbbVie cannot assume that Mavyret will not meet the same unprofitable fate, especially as its sales started to fall in 2018 and then fell sharply by ... | AbbVie faces slow growth from 2020 to 2021 The remainder of this year and most of next year will probably not be an exciting time for AbbVie, as several of its established products face headwinds that will diminish sales. AbbVie in 2025 AbbVie's next five years will largely be characterized by the company working to tr... | Now that it has joined with Allergan, AbbVie has more than 120 pipeline programs, many of which are seeking approval for new indications for its existing drug stable. American biopharma AbbVie (NYSE: ABBV) is renowned for its blockbuster drug, Humira, which was one of the best-selling drugs of the last 20 years. Since ... |
24,512 | 2020-06-11 00:00:00 UTC | AbbVie (ABBV) Shares Cross 5% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-5-yield-mark-2020-06-11 | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.72), with the stock changing hands as low as $92.46 on the day. Dividends are particularly important for investors... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.72), with the stock changing hands as low as $92.46 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, g... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.72), with the stock changing hands as low as $92.46 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, g... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.72), with the stock changing hands as low as $92.46 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, g... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.72), with the stock changing hands as low as $92.46 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, g... |
24,513 | 2020-06-11 00:00:00 UTC | 3 Wins for AbbVie in 3 Days Provide 3 More Good Reasons to Buy the Pharma Stock | ABBV | https://www.nasdaq.com/articles/3-wins-for-abbvie-in-3-days-provide-3-more-good-reasons-to-buy-the-pharma-stock-2020-06-11 | null | null | They say that good things come in threes. And that just might be true for AbbVie (NYSE: ABBV).
The big drugmaker started off the week by receiving good news on Monday. It then announced two positive developments on Wednesday, just in time for the company's top executives to participate in a virtual fireside chat at the... | AbbVie vice chairman and president Michael Severino especially singled out epcoritamab, stating that it "is a strong fit" with the company's successful blood-cancer drugs Imbruvica and Venclexta. And that just might be true for AbbVie (NYSE: ABBV). Here are the three wins for AbbVie in three days that provide three mor... | Encouraging results for ABBV-3373 On Wednesday, AbbVie announced positive results from its phase 2a clinical study evaluating ABBV-3373 in treating rheumatoid arthritis. A big oncology deal The other major news announced by AbbVie on Wednesday was its $3.9 billion oncology deal with Genmab (NASDAQ: GMAB). AbbVie and Ge... | Key legal win for Humira AbbVie has known for a long time that its days of patent exclusivity for Humira were limited. A big oncology deal The other major news announced by AbbVie on Wednesday was its $3.9 billion oncology deal with Genmab (NASDAQ: GMAB). AbbVie and Genmab agreed to jointly develop and market three of ... | If further clinical testing is successful, ABBV-3373 just might mean that Humira (on steroids) continues to make a lot of money for AbbVie well beyond 2023. AbbVie and Genmab agreed to jointly develop and market three of Genmab's bispecific antibody candidates, and collaborate on discovery research related to other ant... |
24,514 | 2020-06-10 00:00:00 UTC | AbbVie To Present At Virtual Goldman Sachs Global Healthcare Conference; Webcast At 10:30 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-virtual-goldman-sachs-global-healthcare-conference-webcast-at-10%3A30 | null | null | (RTTNews) - AbbVie (ABBV) will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference.
The event is scheduled to begin at 10:30 AM ET on June 10, 2020.
To access the live webcast, log on to http://investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the a... | (RTTNews) - AbbVie (ABBV) will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ev... | (RTTNews) - AbbVie (ABBV) will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ev... | (RTTNews) - AbbVie (ABBV) will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ev... | (RTTNews) - AbbVie (ABBV) will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference. To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ev... |
24,515 | 2020-06-10 00:00:00 UTC | Insiders Were Right: ABBV Makes New 52-Week High | ABBV | https://www.nasdaq.com/articles/insiders-were-right%3A-abbv-makes-new-52-week-high-2020-06-10 | null | null | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week high of $98.77/share. That's a 57.91% rise, or $36.22 per share from the 52-week low of $62.55 set back on 03/23/2020. That means at today's intraday high, any investor who purchased ABBV stock any time over the past 52 weeks has an unre... | That means at today's intraday high, any investor who purchased ABBV stock any time over the past 52 weeks has an unrealized gain, including company insiders. As summarized by the table below, ABBV has seen 2 different instances of insiders buying over the trailing six month period. In afternoon trading on Wednesday, A... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week high of $98.77/share. 03/03/2020 Edward J. Rapp Director 2,875 $87.87 $252,617.05 03/20/2020 Brian L. Durkin VP, Controller 3,750 $68.20 $255,754.80 03/20/2020 Brian L. Durkin VP, Controller 1,550 $69.00 $106,950.00 The chart below shows... | That means at today's intraday high, any investor who purchased ABBV stock any time over the past 52 weeks has an unrealized gain, including company insiders. 03/03/2020 Edward J. Rapp Director 2,875 $87.87 $252,617.05 03/20/2020 Brian L. Durkin VP, Controller 3,750 $68.20 $255,754.80 03/20/2020 Brian L. Durkin VP, Con... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week high of $98.77/share. That means at today's intraday high, any investor who purchased ABBV stock any time over the past 52 weeks has an unrealized gain, including company insiders. As summarized by the table below, ABBV has seen 2 differ... |
24,516 | 2020-06-10 00:00:00 UTC | AbbVie Signs $3.9 Billion Oncology Deal with Genmab | ABBV | https://www.nasdaq.com/articles/abbvie-signs-%243.9-billion-oncology-deal-with-genmab-2020-06-10 | null | null | The pace of development for a handful of next-generation cancer therapies is about to get a huge boost. AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down the road.
AbbVie and Genmab wil... | AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down the road. AbbVie and Genmab will jointly develop and commercialize three bispecific antibodies that can target surface proteins found o... | AbbVie and Genmab will jointly develop and commercialize three bispecific antibodies that can target surface proteins found on cancer cells with one side while the other side attracts tumor-hungry immune cells. AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinic... | AbbVie and Genmab will jointly develop and commercialize three bispecific antibodies that can target surface proteins found on cancer cells with one side while the other side attracts tumor-hungry immune cells. AbbVie will pay Genmab $750 million up front and up to $1.15 billion in milestone payments for the three cand... | AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down the road. AbbVie isn't the only big pharmaceutical company investing heavily in bispecific antibody development. AbbVie and Genmab will... |
24,517 | 2020-06-10 00:00:00 UTC | ITOT, ABBV, BMY, COST: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/itot-abbv-bmy-cost%3A-etf-outflow-alert-2020-06-10 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $147.9 million dollar outflow -- that's a 0.6% decrease week over week (from 360,450,000 to ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.9%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.8%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.9%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.8%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.9%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.8%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.9%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.8%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... |
24,518 | 2020-06-10 00:00:00 UTC | Health Care Sector Update for 06/10/2020: CRIS, RKDA, GMAB, ABBV, IBB, XLV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-06-10-2020%3A-cris-rkda-gmab-abbv-ibb-xlv-2020-06-10 | null | null | Shares of health care firms were flat to higher premarket Wednesday. The iShares NASDAQ Biotechnology Index (IBB) was inactive, while the Health Care SPDR (XLV) was 0.21% higher in recent trading.
Curis (CRIS) was surging by more than 79% after saying it has received the US Food and Drug Administration's (FDA) clearanc... | Genmab (GMAB) was up over 4% as it unveiled a collaboration with AbbVie (ABBV) under which potential milestone payments could reach up to $3.15 billion, helping to almost double the Danish biotechnology firm's full-year revenue guidance. AbbVie shares are up 0.5% in premarket trading. The iShares NASDAQ Biotechnology I... | AbbVie shares are up 0.5% in premarket trading. Genmab (GMAB) was up over 4% as it unveiled a collaboration with AbbVie (ABBV) under which potential milestone payments could reach up to $3.15 billion, helping to almost double the Danish biotechnology firm's full-year revenue guidance. Shares of health care firms were f... | Genmab (GMAB) was up over 4% as it unveiled a collaboration with AbbVie (ABBV) under which potential milestone payments could reach up to $3.15 billion, helping to almost double the Danish biotechnology firm's full-year revenue guidance. AbbVie shares are up 0.5% in premarket trading. The iShares NASDAQ Biotechnology I... | Genmab (GMAB) was up over 4% as it unveiled a collaboration with AbbVie (ABBV) under which potential milestone payments could reach up to $3.15 billion, helping to almost double the Danish biotechnology firm's full-year revenue guidance. AbbVie shares are up 0.5% in premarket trading. Shares of health care firms were f... |
24,519 | 2020-06-10 00:00:00 UTC | AbbVie : ABBV-3373 Shows Improvement In Disease Activity In Phase 2a Study On Rheumatoid Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-abbv-3373-shows-improvement-in-disease-activity-in-phase-2a-study-on-rheumatoid | null | null | (RTTNews) - AbbVie (ABBV) said that novel antibody drug conjugate ABBV-3373 showed improvement in disease activity in Phase 2a study of patients with Rheumatoid Arthritis.
The company said that the data showed the clinical activity of ABBV-3373 and supported advancing the development of the platform in rheumatoid arthr... | (RTTNews) - AbbVie (ABBV) said that novel antibody drug conjugate ABBV-3373 showed improvement in disease activity in Phase 2a study of patients with Rheumatoid Arthritis. ABBV-3373 is an investigational novel antibody drug conjugate or ADC comprised of an anti-tumor necrosis factor and a proprietary Glucocorticoid Rec... | (RTTNews) - AbbVie (ABBV) said that novel antibody drug conjugate ABBV-3373 showed improvement in disease activity in Phase 2a study of patients with Rheumatoid Arthritis. The company said that the data showed the clinical activity of ABBV-3373 and supported advancing the development of the platform in rheumatoid arthr... | (RTTNews) - AbbVie (ABBV) said that novel antibody drug conjugate ABBV-3373 showed improvement in disease activity in Phase 2a study of patients with Rheumatoid Arthritis. The company said that the data showed the clinical activity of ABBV-3373 and supported advancing the development of the platform in rheumatoid arthr... | (RTTNews) - AbbVie (ABBV) said that novel antibody drug conjugate ABBV-3373 showed improvement in disease activity in Phase 2a study of patients with Rheumatoid Arthritis. In this study, the safety profile of ABBV-3373 was generally similar to the known safety profile of adalimumab, the company said. In addition, evalu... |
24,520 | 2020-06-10 00:00:00 UTC | Abbvie partners with Genmab in $750 mln cancer therapy deal | ABBV | https://www.nasdaq.com/articles/abbvie-partners-with-genmab-in-%24750-mln-cancer-therapy-deal-2020-06-10-0 | null | null | Adds details of the deal
June 10 (Reuters) - Abbvie Inc ABBV.N said on Wednesday it is partnering with Genmab AS GMAB.CO to jointly develop and commercialize cancer treatment, as it looks to expand its cancer franchise.
The U.S. based pharma giant will pay Genmab $750 million upfront to jointly develop and commercializ... | Adds details of the deal June 10 (Reuters) - Abbvie Inc ABBV.N said on Wednesday it is partnering with Genmab AS GMAB.CO to jointly develop and commercialize cancer treatment, as it looks to expand its cancer franchise. The U.S. based pharma giant will pay Genmab $750 million upfront to jointly develop and commercializ... | Adds details of the deal June 10 (Reuters) - Abbvie Inc ABBV.N said on Wednesday it is partnering with Genmab AS GMAB.CO to jointly develop and commercialize cancer treatment, as it looks to expand its cancer franchise. The U.S. based pharma giant will pay Genmab $750 million upfront to jointly develop and commercializ... | Adds details of the deal June 10 (Reuters) - Abbvie Inc ABBV.N said on Wednesday it is partnering with Genmab AS GMAB.CO to jointly develop and commercialize cancer treatment, as it looks to expand its cancer franchise. The U.S. based pharma giant will pay Genmab $750 million upfront to jointly develop and commercializ... | Adds details of the deal June 10 (Reuters) - Abbvie Inc ABBV.N said on Wednesday it is partnering with Genmab AS GMAB.CO to jointly develop and commercialize cancer treatment, as it looks to expand its cancer franchise. The U.S. based pharma giant will pay Genmab $750 million upfront to jointly develop and commercializ... |
24,521 | 2020-06-10 00:00:00 UTC | AbbVie Signs Broad Collaboration Agreement With Denmark's Genmab - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-signs-broad-collaboration-agreement-with-denmarks-genmab-quick-facts-2020-06-10 | null | null | (RTTNews) - AbbVie (ABBV) and Danish biotechnology company Genmab A/S (GMAB) announced Wednesday that they have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaborati... | (RTTNews) - AbbVie (ABBV) and Danish biotechnology company Genmab A/S (GMAB) announced Wednesday that they have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaborati... | The collaboration combines Genmab's world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie's deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. The discovery research colla... | (RTTNews) - AbbVie (ABBV) and Danish biotechnology company Genmab A/S (GMAB) announced Wednesday that they have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaborati... | (RTTNews) - AbbVie (ABBV) and Danish biotechnology company Genmab A/S (GMAB) announced Wednesday that they have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaborati... |
24,522 | 2020-06-09 00:00:00 UTC | EXPLAINER-What are antibody therapies and who is developing them for COVID-19? | ABBV | https://www.nasdaq.com/articles/explainer-what-are-antibody-therapies-and-who-is-developing-them-for-covid-19-2020-06-09-0 | null | null | By Michael Erman
NEW YORK, June 9 (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise for treating people already infected with the disease.
HOW DO ANTIBODY THERAPIES W... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. By Michael Erman NEW YORK, June 9 (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise fo... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. More recently, scientists have developed treatments called monoclonal antibodies -- antibodies that can be isolated and manufactured in large quantities to treat diseases like Ebola or cancer. The amount of protein in antibody drugs makes t... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. More recently, scientists have developed treatments called monoclonal antibodies -- antibodies that can be isolated and manufactured in large quantities to treat diseases like Ebola or cancer. Regeneron plans to start clinical studies later... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. These therapies use antibodies generated by infected humans or animals to fight off the disease in patients. Designing antibody drugs to treat or protect high risk people, including those with weak immune systems, could require hundreds, or... |
24,523 | 2020-06-09 00:00:00 UTC | EXPLAINER-What are antibody therapies and who is developing them for COVID-19? | ABBV | https://www.nasdaq.com/articles/explainer-what-are-antibody-therapies-and-who-is-developing-them-for-covid-19-2020-06-09 | null | null | By Michael Erman
NEW YORK, June 9 (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise for treating people already infected with the disease.
HOW DO ANTIBODY THERAPIES W... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. By Michael Erman NEW YORK, June 9 (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise fo... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. For COVID-19 treatment, researchers are studying the use of convalescent plasma and other treatments made with blood from recently recovered patients. More recently, scientists have developed treatments called monoclonal antibodies -- antib... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. More recently, scientists have developed treatments called monoclonal antibodies -- antibodies that can be isolated and manufactured in large quantities to treat diseases like Ebola or cancer. Regeneron plans to start clinical studies later... | AbbVie ABBV.N has also announced a collaboration to develop antibody therapies. These therapies use antibodies generated by infected humans or animals to fight off the disease in patients. For COVID-19 treatment, researchers are studying the use of convalescent plasma and other treatments made with blood from recently ... |
24,524 | 2020-06-07 00:00:00 UTC | AstraZeneca contacted Gilead over potential megamerger -Bloomberg News | ABBV | https://www.nasdaq.com/articles/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-2020-06-07 | null | null | By Paul Sandle and Pamela Barbaglia
LONDON, June 7 (Reuters) - Britain's AstraZeneca AZN.L has approached U.S. rival Gilead Sciences GILD.O about a possible merger to form one the world's largest drug companies, Bloomberg News reported on Sunday, citing people familiar with the matter.
Such a deal would unite two of th... | U.S. drugmaker Bristol Myers Squibb BMY.N completed its $74 billion acquisition of Celgene in November and AbbVie ABBV.N is buying Botox maker Allergan AGN.N in a $63 billion deal. By Paul Sandle and Pamela Barbaglia LONDON, June 7 (Reuters) - Britain's AstraZeneca AZN.L has approached U.S. rival Gilead Sciences GILD.O... | U.S. drugmaker Bristol Myers Squibb BMY.N completed its $74 billion acquisition of Celgene in November and AbbVie ABBV.N is buying Botox maker Allergan AGN.N in a $63 billion deal. By Paul Sandle and Pamela Barbaglia LONDON, June 7 (Reuters) - Britain's AstraZeneca AZN.L has approached U.S. rival Gilead Sciences GILD.O... | U.S. drugmaker Bristol Myers Squibb BMY.N completed its $74 billion acquisition of Celgene in November and AbbVie ABBV.N is buying Botox maker Allergan AGN.N in a $63 billion deal. By Paul Sandle and Pamela Barbaglia LONDON, June 7 (Reuters) - Britain's AstraZeneca AZN.L has approached U.S. rival Gilead Sciences GILD.O... | U.S. drugmaker Bristol Myers Squibb BMY.N completed its $74 billion acquisition of Celgene in November and AbbVie ABBV.N is buying Botox maker Allergan AGN.N in a $63 billion deal. By Paul Sandle and Pamela Barbaglia LONDON, June 7 (Reuters) - Britain's AstraZeneca AZN.L has approached U.S. rival Gilead Sciences GILD.O... |
24,525 | 2020-06-07 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2020-06-07 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are stalwart companies that are in a lot of investors' portfolios. Analysts almost always preach diversification, and these two healthcare stocks bring balance in their own right.
AbbVie is strictly pharmaceutical, but its recent purchase of Allergan really broadens... | AbbVie is strictly pharmaceutical, but its recent purchase of Allergan really broadens its pipeline beyond the world's top-selling drug, Humira, which treats many auto-immune disorders. Buying Allergan gives AbbVie Botox, a cash cow that made the former company $1.02 billion in sales in the fourth quarter, with slightl... | In AbbVie's first-quarter report, revenue was $8.6 billion, an increase of 10.1%, year over year. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are stalwart companies that are in a lot of investors' portfolios. AbbVie is strictly pharmaceutical, but its recent purchase of Allergan really broadens its pipeline b... | The case for AbbVie AbbVie boasted more growth recently than Johnson & Johnson and that should accelerate with its purchase of Allergan that was completed in May. At this point, AbbVie appears to be a better deal Looking at the potential upside for AbbVie from the Allergan deal, I believe its stock is underpriced, comp... | The case for AbbVie AbbVie boasted more growth recently than Johnson & Johnson and that should accelerate with its purchase of Allergan that was completed in May. Not only has AbbVie had more growth this year in its share price, at 7% compared to Johnson & Johnson's 1.7% rise; it has a significantly lower price-to-earn... |
24,526 | 2020-06-06 00:00:00 UTC | If You Like Dividends, You Should Love These 2 Stocks | ABBV | https://www.nasdaq.com/articles/if-you-like-dividends-you-should-love-these-2-stocks-2020-06-06 | null | null | Amid the coronavirus-fueled market downturn -- and the economic troubles that have followed -- many companies have slashed or outright suspended their dividend payments, much to the dismay of income-seeking investors. However, some companies look poised to ride out the current market downturn with their dividends unsca... | Skyrizi is another promising product for AbbVie; revenue from this plaque psoriasis treatment -- which was approved last year by the U.S. Food and Drug Administration (FDA) -- totaled $300 million during the first quarter, a roughly 39% sequential increase. Two such businesses are healthcare giants AbbVie (NYSE: ABBV) ... | Two such businesses are healthcare giants AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). ABBV data by YCharts The new AbbVie could be a cash-making machine AbbVie currently sports a dividend yield of 4.8%, a dividend payout ratio of 77.5%, and a cash payout ratio of 48.3%. AbbVie markets Humira, the world's best-selling d... | AbbVie looks likely to continue rewarding its shareholders by way of dividend increases for many years, and income-seeking investors would do well to consider buying shares of the pharma giant. Two such businesses are healthcare giants AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). ABBV data by YCharts The new AbbVie coul... | AbbVie looks likely to continue rewarding its shareholders by way of dividend increases for many years, and income-seeking investors would do well to consider buying shares of the pharma giant. Two such businesses are healthcare giants AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). ABBV data by YCharts The new AbbVie coul... |
24,527 | 2020-06-06 00:00:00 UTC | 2 Healthcare Stocks That Have a Killer Advantage | ABBV | https://www.nasdaq.com/articles/2-healthcare-stocks-that-have-a-killer-advantage-2020-06-06 | null | null | Making money on the stock market is simple, at least in theory. All an investor needs to do is to buy shares of public companies that have a competitive advantage -- and that, as a result, can continue generating growing revenue and earnings for decades -- and hold these shares for a long time.
But it isn't always simp... | For instance, pharma giant AbbVie (NYSE: ABBV) has an investigational CF drug in early-stage testing. But AbbVie's product isn't even close to hitting the market, that is, if it ever does. During the fourth quarter of its fiscal year 2019, Vertex recorded net revenue of $1.4 billion, a 63% year-over-year increase. | For instance, pharma giant AbbVie (NYSE: ABBV) has an investigational CF drug in early-stage testing. But AbbVie's product isn't even close to hitting the market, that is, if it ever does. This company holds a monopoly in the market for CF drugs Vertex Pharma is a biotech company that has one of the most compelling com... | For instance, pharma giant AbbVie (NYSE: ABBV) has an investigational CF drug in early-stage testing. But AbbVie's product isn't even close to hitting the market, that is, if it ever does. This company holds a monopoly in the market for CF drugs Vertex Pharma is a biotech company that has one of the most compelling com... | For instance, pharma giant AbbVie (NYSE: ABBV) has an investigational CF drug in early-stage testing. But AbbVie's product isn't even close to hitting the market, that is, if it ever does. However, 2025 isn't exactly around the corner, and Trikafta -- by far Vertex's most important drug to date, which already accounts ... |
24,528 | 2020-06-05 00:00:00 UTC | Strong Insider Buying Found in the Underlying Holdings of DHS | ABBV | https://www.nasdaq.com/articles/strong-insider-buying-found-in-the-underlying-holdings-of-dhs-2020-06-05 | null | null | A look at the weighted underlying holdings of the WisdomTree U.S. High Dividend Fund (DHS) shows an impressive 28.7% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 5.34% of the WisdomTree U.S. High Dividend Fund (DHS), has seen 2 dir... | AbbVie Inc (Symbol: ABBV), which makes up 5.34% of the WisdomTree U.S. High Dividend Fund (DHS), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $39,694,837 worth of ABBV, making it the #3 largest holding. The table below details th... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $93.04 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 5.34% of the WisdomTree U.S. High Dividend Fund (DHS), has seen 2 directors and officers purchase shares in the past six months, according to the recent... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $93.04 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 5.34% of the WisdomTree U.S. High Dividend Fund (DHS), has seen 2 directors and officers purchase shares in the past six months, according to the recent... | AbbVie Inc (Symbol: ABBV), which makes up 5.34% of the WisdomTree U.S. High Dividend Fund (DHS), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $39,694,837 worth of ABBV, making it the #3 largest holding. The table below details th... |
24,529 | 2020-06-05 00:00:00 UTC | AbbVie, HBM, UU, Erasmus Medical Center To Develop Antibody Therapeutic To Prevent & Treat COVID-19 | ABBV | https://www.nasdaq.com/articles/abbvie-hbm-uu-erasmus-medical-center-to-develop-antibody-therapeutic-to-prevent-treat | null | null | (RTTNews) - AbbVie (ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center have collaborated to develop a novel antibody therapeutic to prevent and treat COVID-19, AbbVie said in a statement.
They will focus on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM... | As per the terms of the collaboration, AbbVie will support Utrecht University, Erasmus Medical Center and Harbour BioMed through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. AbbVie will receive an option to exclusively license the a... | (RTTNews) - AbbVie (ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center have collaborated to develop a novel antibody therapeutic to prevent and treat COVID-19, AbbVie said in a statement. As per the terms of the collaboration, AbbVie will support Utrecht University, Erasmus Medical Center a... | (RTTNews) - AbbVie (ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center have collaborated to develop a novel antibody therapeutic to prevent and treat COVID-19, AbbVie said in a statement. As per the terms of the collaboration, AbbVie will support Utrecht University, Erasmus Medical Center a... | (RTTNews) - AbbVie (ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center have collaborated to develop a novel antibody therapeutic to prevent and treat COVID-19, AbbVie said in a statement. As per the terms of the collaboration, AbbVie will support Utrecht University, Erasmus Medical Center a... |
24,530 | 2020-06-05 00:00:00 UTC | Abbvie strikes partnership to develop COVID-19 antibody therapy | ABBV | https://www.nasdaq.com/articles/abbvie-strikes-partnership-to-develop-covid-19-antibody-therapy-2020-06-05 | null | null | June 5 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N said on Friday it would develop an antibody therapy to prevent and treat COVID-19 in partnership with three organizations including the Netherlands' Utrecht University.
AbbVie joins other drugmakers in the race to develop a treatment for COVID-19, the respiratory illn... | June 5 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N said on Friday it would develop an antibody therapy to prevent and treat COVID-19 in partnership with three organizations including the Netherlands' Utrecht University. AbbVie joins other drugmakers in the race to develop a treatment for COVID-19, the respiratory illn... | AbbVie will support through the preclinical phase, as well as prepare for later stage preclinical and clinical development work. June 5 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N said on Friday it would develop an antibody therapy to prevent and treat COVID-19 in partnership with three organizations including the Net... | June 5 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N said on Friday it would develop an antibody therapy to prevent and treat COVID-19 in partnership with three organizations including the Netherlands' Utrecht University. AbbVie joins other drugmakers in the race to develop a treatment for COVID-19, the respiratory illn... | AbbVie joins other drugmakers in the race to develop a treatment for COVID-19, the respiratory illness caused by the new coronavirus that has no approved treatment. AbbVie will support through the preclinical phase, as well as prepare for later stage preclinical and clinical development work. June 5 (Reuters) - U.S. dr... |
24,531 | 2020-06-04 00:00:00 UTC | AbbVie's : Long-term Results Show RINVOQ Improves Signs, Symptoms On Rheumatoid Arthritis | ABBV | https://www.nasdaq.com/articles/abbvies-%3A-long-term-results-show-rinvoq-improves-signs-symptoms-on-rheumatoid-arthritis | null | null | (RTTNews) - AbbVie (ABBV) announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively.
The safety p... | (RTTNews) - AbbVie (ABBV) announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively. RINVOQ, a se... | (RTTNews) - AbbVie (ABBV) announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively. RINVOQ, a se... | (RTTNews) - AbbVie (ABBV) announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively. RINVOQ, a se... | (RTTNews) - AbbVie (ABBV) announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively. RINVOQ, a se... |
24,532 | 2020-06-03 00:00:00 UTC | Why Editas Medicine Is Now the CRISPR Stock to Really Watch | ABBV | https://www.nasdaq.com/articles/why-editas-medicine-is-now-the-crispr-stock-to-really-watch-2020-06-03 | null | null | Based on market cap, CRISPR Therapeutics (NASDAQ: CRSP) ranks as the top biotech focused on developing CRISPR gene-editing therapies. It's more than 2 1/2 times the size of Editas Medicine (NASDAQ: EDIT) and nearly four times larger than Intellia Therapeutics (NASDAQ: NTLA).
But based on stock performance so far in 202... | Its partner on EDIT-101, Allergan, was recently acquired by AbbVie (NYSE: ABBV). The primary reason for this deal was for AbbVie to reduce its dependence on Humira, which faces biosimilar competition in the U.S. beginning in 2023. AbbVie has other arrows in its quiver for offsetting the inevitable loss of revenue from ... | Buying Editas could also boost AbbVie's oncology program since Editas has several preclinical programs that use CRISPR gene editing in cancer cell therapies. Its partner on EDIT-101, Allergan, was recently acquired by AbbVie (NYSE: ABBV). The primary reason for this deal was for AbbVie to reduce its dependence on Humir... | Buying Editas could also boost AbbVie's oncology program since Editas has several preclinical programs that use CRISPR gene editing in cancer cell therapies. Its partner on EDIT-101, Allergan, was recently acquired by AbbVie (NYSE: ABBV). The primary reason for this deal was for AbbVie to reduce its dependence on Humir... | Its partner on EDIT-101, Allergan, was recently acquired by AbbVie (NYSE: ABBV). The primary reason for this deal was for AbbVie to reduce its dependence on Humira, which faces biosimilar competition in the U.S. beginning in 2023. AbbVie has other arrows in its quiver for offsetting the inevitable loss of revenue from ... |
24,533 | 2020-06-03 00:00:00 UTC | Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk | ABBV | https://www.nasdaq.com/articles/abbvie-stock-is-offering-investors-an-oil-yield-without-oils-risk-2020-06-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
How would you like the yield of an oil stock without the risks of buying one? That’s what you can get with Abbvie (NASDAQ:ABBV). The beta on ABBV stock is 0.78; The similarly yielding but more-risky Chevron (NYSE:CVX) sports a beta of 1.33.
Source: Piotr Sw... | Abbvie also has high hopes for Oriahnn and Orilissa, which reduce menstrual bleeding and can prevent uterine fibroids, a leading cause of hysterectomies. That’s what you can get with Abbvie (NASDAQ:ABBV). The beta on ABBV stock is 0.78; The similarly yielding but more-risky Chevron (NYSE:CVX) sports a beta of 1.33. | The Monopoly Problem Humira has been bringing Abbvie $20 billion a year and the company has been pushing its price aggressively. Bottom Line on ABBV Stock The Allergan pipeline has been lined up to replace Humira revenue as competition in its niche heats up. The post Abbvie Stock is Offering Investors an Oil Yield With... | The Monopoly Problem Humira has been bringing Abbvie $20 billion a year and the company has been pushing its price aggressively. The post Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk appeared first on InvestorPlace. That’s what you can get with Abbvie (NASDAQ:ABBV). | The Monopoly Problem Humira has been bringing Abbvie $20 billion a year and the company has been pushing its price aggressively. That’s what you can get with Abbvie (NASDAQ:ABBV). The beta on ABBV stock is 0.78; The similarly yielding but more-risky Chevron (NYSE:CVX) sports a beta of 1.33. |
24,534 | 2020-06-02 00:00:00 UTC | AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives | ABBV | https://www.nasdaq.com/articles/abbvie-will-be-in-big-trouble-when-its-patent-cliff-arrives-2020-06-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical devices company Abbott (NYSE:ABT). Now, however, AbbVie must adapt quickly or ABBV stock will be in big trouble.
Up ... | AbbVie began life about a decade ago when it was spun off from health care and medical devices company Abbott (NYSE:ABT). I suspect that if AbbVie paid a similarly modest yield, its stock would be much less popular with individual investors. Particularly in the post-coronavirus world, when companies are slashing their ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NASDAQ:ABBV) is in the midst of a transition. Up until recently, AbbVie relied on its blockbuster Humira drug for around 60% of its revenue. AbbVie’s High Yield Reflects Its Inherent Risk Sometimes a company offers a high dividend simply because the... | AbbVie spent more than $60 billion on Allergan to try to fill its upcoming Humira revenue hole. AbbVie’s Dividend Is Its Main Attraction AbbVie has attracted a ton of attention from investors primarily because it pays a huge dividend. AbbVie’s High Yield Reflects Its Inherent Risk Sometimes a company offers a high div... | With a great deal of that revenue set to disappear in 2023, why have investors been bidding up ABBV stock recently? InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical ... |
24,535 | 2020-06-02 00:00:00 UTC | iShares Edge MSCI USA Momentum Factor ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-edge-msci-usa-momentum-factor-etf-experiences-big-outflow-2020-06-02 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $177.2 million dollar outflow -- that's a 1.8% decrease week over week (from 76,150,000 to 74,7... | Among the largest underlying components of MTUM, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 1%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one ... | Among the largest underlying components of MTUM, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 1%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one ... | Among the largest underlying components of MTUM, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of MTUM, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, Bristol-Myers Squibb Co. (Symbol: BMY) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... |
24,536 | 2020-06-02 00:00:00 UTC | AbbVie Stock Is a Winner in the Pharmaceutical Industry | ABBV | https://www.nasdaq.com/articles/abbvie-stock-is-a-winner-in-the-pharmaceutical-industry-2020-06-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The Covid-19 pandemic has had serious implications on businesses across the globe, but AbbVie (NYSE:ABBV) stock is thriving amidst the chaos. As the virus continues to spread across the nation with the emergence of new hotspots, the need for a vaccine is no... | As companies struggle to keep their heads above water, AbbVie has successfully acquired a major player in the pharmaceutical industry while making waves with Humira in the U.S market. ABBV stock is expected to dish out some serious returns in the upcoming years so we recommend you stay bullish on this buy despite the c... | Humira Shines In U.S Markets ABBV stock faced numerous challenges in 2019 and acquired Humira with hopes of diversifying their growth. These products help the company’s growth remain stable, making ABBV stock a sound investment. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Covid-19 pandemic has ha... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Covid-19 pandemic has had serious implications on businesses across the globe, but AbbVie (NYSE:ABBV) stock is thriving amidst the chaos. As companies see their market valuations evaporate, ABBV stock proves to be a safe bet for investors in an increasi... | ABBV Stock Is a Winner for Dividends AbbVie’s acquisitions have set them up for long-term success and this is reflective in ABBV stock’s prices. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Covid-19 pandemic has had serious implications on businesses across the globe, but AbbVie (NYSE:ABBV) stock ... |
24,537 | 2020-06-02 00:00:00 UTC | 3 Stocks With Dividends Yielding More Than 3% | ABBV | https://www.nasdaq.com/articles/3-stocks-with-dividends-yielding-more-than-3-2020-06-02 | null | null | Dividend yield is an important factor investors consider when choosing a dividend stock to invest in. A high yield might be unsustainable, while a low one might not be enticing enough to attract investors. The typical yield from an S&P 500 stock is about 2% per year. However, investors can still do better than that wit... | AbbVie AbbVie (NYSE: ABBV) is a global drug manufacturer that got a whole lot stronger and more diversified this year. The $63 billion deal will give AbbVie access to Ubrelvy, a key migraine drug the Food and Drug Administration (FDA) approved in December. On its own, AbbVie generated more than $30 billion in revenue i... | With the acquisition, AbbVie is a stronger company, and that's great news for dividend investors, especially during the COVID-19 pandemic. AbbVie AbbVie (NYSE: ABBV) is a global drug manufacturer that got a whole lot stronger and more diversified this year. The $63 billion deal will give AbbVie access to Ubrelvy, a key... | AbbVie AbbVie (NYSE: ABBV) is a global drug manufacturer that got a whole lot stronger and more diversified this year. The $63 billion deal will give AbbVie access to Ubrelvy, a key migraine drug the Food and Drug Administration (FDA) approved in December. On its own, AbbVie generated more than $30 billion in revenue i... | With the acquisition, AbbVie is a stronger company, and that's great news for dividend investors, especially during the COVID-19 pandemic. AbbVie AbbVie (NYSE: ABBV) is a global drug manufacturer that got a whole lot stronger and more diversified this year. The $63 billion deal will give AbbVie access to Ubrelvy, a key... |
24,538 | 2020-06-02 00:00:00 UTC | 7 High-Dividend Stocks With Durable Distributions | ABBV | https://www.nasdaq.com/articles/7-high-dividend-stocks-with-durable-distributions-2020-06-02 | null | null | The market's violent rebound since the March 23 lows has been a welcome relief for long-term shareholders and a boon for dip buyers. But one group of investors has actually been put out by the rally: income investors looking to put dry powder to work in high-dividend stocks.
As the S&P 500 has crashed and recovered, it... | SEE ALSO: 32 Ways to Earn Up to 9% on Your Money Now AbbVie Market value: $159.8 billion Dividend yield: 5.2% DIVCON Rating: 4 DIVCON Score: 59 AbbVie (ABBV, $90.70) is a pharmaceutical company that's primarily known for Humira, which treats several conditions (including rheumatoid arthritis and plaque psoriasis) and a... | SEE ALSO: 32 Ways to Earn Up to 9% on Your Money Now AbbVie Market value: $159.8 billion Dividend yield: 5.2% DIVCON Rating: 4 DIVCON Score: 59 AbbVie (ABBV, $90.70) is a pharmaceutical company that's primarily known for Humira, which treats several conditions (including rheumatoid arthritis and plaque psoriasis) and a... | SEE ALSO: 32 Ways to Earn Up to 9% on Your Money Now AbbVie Market value: $159.8 billion Dividend yield: 5.2% DIVCON Rating: 4 DIVCON Score: 59 AbbVie (ABBV, $90.70) is a pharmaceutical company that's primarily known for Humira, which treats several conditions (including rheumatoid arthritis and plaque psoriasis) and a... | SEE ALSO: 32 Ways to Earn Up to 9% on Your Money Now AbbVie Market value: $159.8 billion Dividend yield: 5.2% DIVCON Rating: 4 DIVCON Score: 59 AbbVie (ABBV, $90.70) is a pharmaceutical company that's primarily known for Humira, which treats several conditions (including rheumatoid arthritis and plaque psoriasis) and a... |
24,539 | 2020-06-01 00:00:00 UTC | AbbVie, Jacobio Collaborate To Develop And Commercialize SHP2 Inhibitors | ABBV | https://www.nasdaq.com/articles/abbvie-jacobio-collaborate-to-develop-and-commercialize-shp2-inhibitors-2020-06-01 | null | null | (RTTNews) - AbbVie (ABBV) and Jacobio Pharmaceuticals have collaborated to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. Financial terms were not disclosed.
As per the terms of the deal, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will cont... | (RTTNews) - AbbVie (ABBV) and Jacobio Pharmaceuticals have collaborated to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. As per the terms of the deal, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinica... | Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. (RTTNews) - AbbVie (ABBV) and Jacobio Pharmaceuticals have collaborated to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. As per the terms of the deal... | (RTTNews) - AbbVie (ABBV) and Jacobio Pharmaceuticals have collaborated to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. As per the terms of the deal... | (RTTNews) - AbbVie (ABBV) and Jacobio Pharmaceuticals have collaborated to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. As per the terms of the deal... |
24,540 | 2020-05-30 00:00:00 UTC | Is Pfizer a Great Dividend Stock? | ABBV | https://www.nasdaq.com/articles/is-pfizer-a-great-dividend-stock-2020-05-30 | null | null | Facing economic uncertainties or prolonged downturns, investors typically seek the safe haven of defensive stocks. Large multinational pharmaceutical companies fall into this category. Illness does not know or care about economic conditions, causing individuals to seek treatment for what ails them. While not entirely r... | However, AbbVie and GlaxoSmithKline pay dividends yielding approximately 4.9%. Facing economic uncertainties or prolonged downturns, investors typically seek the safe haven of defensive stocks. The household name famous for blockbuster drugs like Lipitor, Lyrica, and Viagra expects 2020 to be a transformational year as... | However, AbbVie and GlaxoSmithKline pay dividends yielding approximately 4.9%. By owning Pfizer shares before the transaction, investors will end the year with two dividend-paying stocks in their portfolios. Excluding Upjohn for the year -- what it dubs "New Pfizer" -- revenue guidance ranges from $40.7 billion to $42.... | However, AbbVie and GlaxoSmithKline pay dividends yielding approximately 4.9%. Pfizer's dividend When it comes to dividend yield, Pfizer takes third place on the podium again. Not one, but two dividends Last summer Pfizer announced that it will spin off its generic drugs unit Upjohn and merge it with another global gen... | However, AbbVie and GlaxoSmithKline pay dividends yielding approximately 4.9%. Think of it as a dividend in the stock in the new company. Owning a solid company like Pfizer provides steady income of around 4% through its dividend yield despite the current coronavirus pandemic. |
24,541 | 2020-05-30 00:00:00 UTC | FDA Oks AbbVie's Oriahnn To Treat Heavy Menstrual Bleeding Associated With Fibroids In Women | ABBV | https://www.nasdaq.com/articles/fda-oks-abbvies-oriahnn-to-treat-heavy-menstrual-bleeding-associated-with-fibroids-in | null | null | (RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), said that the U.S. Food and Drug Administration approved Oriahnn capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
The approval provid... | (RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), said that the U.S. Food and Drug Administration approved Oriahnn capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The approval provid... | (RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), said that the U.S. Food and Drug Administration approved Oriahnn capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The approval provid... | (RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), said that the U.S. Food and Drug Administration approved Oriahnn capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The FDA warned that... | (RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), said that the U.S. Food and Drug Administration approved Oriahnn capsules, co-packaged for oral use, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The approval provid... |
24,542 | 2020-05-29 00:00:00 UTC | FDA approves Abbvie's treatment to control menstrual bleeding | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-treatment-to-control-menstrual-bleeding-2020-05-29 | null | null | May 29 (Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc's ABBV.N oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women.
Fibroids are benign muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems a... | May 29 (Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc's ABBV.N oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women. Fibroids are benign muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems a... | May 29 (Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc's ABBV.N oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women. Fibroids are benign muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems a... | May 29 (Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc's ABBV.N oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women. Fibroids are benign muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems a... | May 29 (Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc's ABBV.N oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women. Fibroids are benign muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems a... |
24,543 | 2020-05-28 00:00:00 UTC | Analysts Expect FXH To Hit $98 | ABBV | https://www.nasdaq.com/articles/analysts-expect-fxh-to-hit-%2498-2020-05-28 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDE... | First Trust Health Care AlphaDEX Fund ETF FXH $89.09 $97.90 9.89% Insulet Corp PODD $178.43 $206.00 15.45% Alnylam Pharmaceuticals Inc ALNY $133.35 $153.16 14.85% AbbVie Inc ABBV $89.98 $100.64 11.84% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from n... | Three of FXH's underlying holdings with notable upside to their analyst target prices are Insulet Corp (Symbol: PODD), Alnylam Pharmaceuticals Inc (Symbol: ALNY), and AbbVie Inc (Symbol: ABBV). First Trust Health Care AlphaDEX Fund ETF FXH $89.09 $97.90 9.89% Insulet Corp PODD $178.43 $206.00 15.45% Alnylam Pharmaceuti... | Similarly, ALNY has 14.85% upside from the recent share price of $133.35 if the average analyst target price of $153.16/share is reached, and analysts on average are expecting ABBV to reach a target price of $100.64/share, which is 11.84% above the recent price of $89.98. Three of FXH's underlying holdings with notable... | First Trust Health Care AlphaDEX Fund ETF FXH $89.09 $97.90 9.89% Insulet Corp PODD $178.43 $206.00 15.45% Alnylam Pharmaceuticals Inc ALNY $133.35 $153.16 14.85% AbbVie Inc ABBV $89.98 $100.64 11.84% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from n... |
24,544 | 2020-05-27 00:00:00 UTC | The 3 Best Stocks for Beginning Investors | ABBV | https://www.nasdaq.com/articles/the-3-best-stocks-for-beginning-investors-2020-05-27 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you’d invested $143 in the S&P 500 in 1928, reinvesting all dividends, at the end of 2019, your initial investment would be worth $502,417, according to Aswath Damodaran, Professor of Finance at New York University Stern School of Business. That simple p... | Abbvie (NYSE:ABBV) Stocks for Beginners: Snap-On (SNA) Source: RMC42/ShutterStock.com Snap-on manufactures tools, equipment, diagnostics and solutions for repairing vehicles, planes and other types of industrial equipment. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com This biopharmaceutical company develops and m... | Abbvie (NYSE:ABBV) Stocks for Beginners: Snap-On (SNA) Source: RMC42/ShutterStock.com Snap-on manufactures tools, equipment, diagnostics and solutions for repairing vehicles, planes and other types of industrial equipment. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com This biopharmaceutical company develops and m... | Abbvie (NYSE:ABBV) Stocks for Beginners: Snap-On (SNA) Source: RMC42/ShutterStock.com Snap-on manufactures tools, equipment, diagnostics and solutions for repairing vehicles, planes and other types of industrial equipment. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com This biopharmaceutical company develops and m... | Abbvie (NYSE:ABBV) Stocks for Beginners: Snap-On (SNA) Source: RMC42/ShutterStock.com Snap-on manufactures tools, equipment, diagnostics and solutions for repairing vehicles, planes and other types of industrial equipment. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com This biopharmaceutical company develops and m... |
24,545 | 2020-05-27 00:00:00 UTC | Ironwood, AbbVie To Discontinue Development Of MD-7246 - Quick Facts | ABBV | https://www.nasdaq.com/articles/ironwood-abbvie-to-discontinue-development-of-md-7246-quick-facts-2020-05-27 | null | null | (RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) reported that its Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea did not meet primary or key secondary endpoints. Ironwood and AbbVie plan to discontinue the development of MD-7246.
MD-7246 ... | MD-7246 is a delayed release formulation of linaclotide that was being evaluated by Ironwood and its partner AbbVie as an oral, non-opioid, pain-relieving agent for adult patients in the U.S. suffering from abdominal pain associated irritable bowel syndrome with diarrhea. Ironwood and AbbVie plan to discontinue the dev... | Ironwood and AbbVie plan to discontinue the development of MD-7246. MD-7246 is a delayed release formulation of linaclotide that was being evaluated by Ironwood and its partner AbbVie as an oral, non-opioid, pain-relieving agent for adult patients in the U.S. suffering from abdominal pain associated irritable bowel syn... | MD-7246 is a delayed release formulation of linaclotide that was being evaluated by Ironwood and its partner AbbVie as an oral, non-opioid, pain-relieving agent for adult patients in the U.S. suffering from abdominal pain associated irritable bowel syndrome with diarrhea. Ironwood and AbbVie plan to discontinue the dev... | Ironwood and AbbVie plan to discontinue the development of MD-7246. MD-7246 is a delayed release formulation of linaclotide that was being evaluated by Ironwood and its partner AbbVie as an oral, non-opioid, pain-relieving agent for adult patients in the U.S. suffering from abdominal pain associated irritable bowel syn... |
24,546 | 2020-05-26 00:00:00 UTC | Is Coherus BioSciences a Buy? | ABBV | https://www.nasdaq.com/articles/is-coherus-biosciences-a-buy-2020-05-26 | null | null | Coherus BioSciences (NASDAQ: CHRS) is a shining example of success in the otherwise failure-filled field of biosimilars. The company's first major product, Udenyca, was the most successful drug launch of 2019. Its quick traction flipped an operating loss of $204 million in 2018 to an operating profit of $107 million la... | It has continuously expanded development opportunities by inking licensing deals with outside drug developers and working out agreements with innovators, such as AbbVie, to earn the right to smoothly launch biosimilars to their drugs, such as Humira, in the future. Advance ophthalmology product candidates: Coherus BioS... | It has continuously expanded development opportunities by inking licensing deals with outside drug developers and working out agreements with innovators, such as AbbVie, to earn the right to smoothly launch biosimilars to their drugs, such as Humira, in the future. Coherus BioSciences ended March with $193 million in c... | It has continuously expanded development opportunities by inking licensing deals with outside drug developers and working out agreements with innovators, such as AbbVie, to earn the right to smoothly launch biosimilars to their drugs, such as Humira, in the future. Considering seven of the top 10 best-selling drug prod... | It has continuously expanded development opportunities by inking licensing deals with outside drug developers and working out agreements with innovators, such as AbbVie, to earn the right to smoothly launch biosimilars to their drugs, such as Humira, in the future. The company's first major product, Udenyca, was the mo... |
24,547 | 2020-05-26 00:00:00 UTC | WHO expects hydroxychloroquine safety findings by mid-June | ABBV | https://www.nasdaq.com/articles/who-expects-hydroxychloroquine-safety-findings-by-mid-june-2020-05-26 | null | null | Adds details
ZURICH, May 26 (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probablyby mid-June, after safety concerns prompted the group to suspend the malaria drug's use in a trial on COVID-19 patients.
U.S. President Donald Trump and others have pushe... | Newly enrolled patients will receive other treatments being evaluated in Solidarity, including Gilead Science's GILD.O remdesivir and AbbVie's ABBV.N Kaletra/Aluvia. Adds details ZURICH, May 26 (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probablyby m... | Newly enrolled patients will receive other treatments being evaluated in Solidarity, including Gilead Science's GILD.O remdesivir and AbbVie's ABBV.N Kaletra/Aluvia. Adds details ZURICH, May 26 (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probablyby m... | Newly enrolled patients will receive other treatments being evaluated in Solidarity, including Gilead Science's GILD.O remdesivir and AbbVie's ABBV.N Kaletra/Aluvia. Adds details ZURICH, May 26 (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probablyby m... | Newly enrolled patients will receive other treatments being evaluated in Solidarity, including Gilead Science's GILD.O remdesivir and AbbVie's ABBV.N Kaletra/Aluvia. Adds details ZURICH, May 26 (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probablyby m... |
24,548 | 2020-05-24 00:00:00 UTC | Is Vertex Pharmaceuticals Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-vertex-pharmaceuticals-stock-a-buy-2020-05-24 | null | null | The answer is yes. There's no need to build any suspense. Vertex Pharmaceuticals (NASDAQ: VRTX) is definitely a great stock to buy right now, in my view.
I've owned the biotech stock for a couple of years. I bought more shares recently as Vertex was rebounding from the stock market sell-off caused by the COVID-19 pande... | AbbVie's pipeline includes a couple of experimental CF programs in phase 2 clinical studies. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. Its drugs will be prescribed by physicians, paid for by insurers and government agencies, and taken ... | AbbVie's pipeline includes a couple of experimental CF programs in phase 2 clinical studies. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. Multiple paths for growth In addition to Vertex's strong moat, the company has multiple paths for gr... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. AbbVie's pipeline includes a couple of experimental CF programs in phase 2 clinical studies. That's because Vertex markets the only approved drugs that treat the underlying cause of cystic fibr... | AbbVie's pipeline includes a couple of experimental CF programs in phase 2 clinical studies. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. Why do I like Vertex so much? |
24,549 | 2020-05-22 00:00:00 UTC | Should You Own This Sleeper Biotech Stock? | ABBV | https://www.nasdaq.com/articles/should-you-own-this-sleeper-biotech-stock-2020-05-22 | null | null | The sheer volume of biotech IPOs over the past few years makes it challenging to keep up to date on all these newly public companies. Several have returned to the capital markets to load up on cash to fund ongoing research and development (R&D) efforts. Among this crowd, Y-mAbs Therapeutics (NASDAQ: YMAB) continues to ... | It sold the voucher in 2015 to AbbVie for $350 million, representing the highest amount ever paid for a voucher. Targeting pediatric brain cancer Y-mAbs's lead drug candidate, naxitamab, aims to be the first choice for maintenance therapy for patients with relapsed or refractory neuroblastoma. On March 31, the company ... | It sold the voucher in 2015 to AbbVie for $350 million, representing the highest amount ever paid for a voucher. Targeting pediatric brain cancer Y-mAbs's lead drug candidate, naxitamab, aims to be the first choice for maintenance therapy for patients with relapsed or refractory neuroblastoma. According to the National... | It sold the voucher in 2015 to AbbVie for $350 million, representing the highest amount ever paid for a voucher. Targeting pediatric brain cancer Y-mAbs's lead drug candidate, naxitamab, aims to be the first choice for maintenance therapy for patients with relapsed or refractory neuroblastoma. According to the National... | It sold the voucher in 2015 to AbbVie for $350 million, representing the highest amount ever paid for a voucher. These vouchers can be used for any new drug application, not just those targeting rare diseases, to expedite the FDA's review time from the standard 10 months to six months. 10 stocks we like better than Y-M... |
24,550 | 2020-05-22 00:00:00 UTC | Better Buy: AbbVie vs. Eli Lilly | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-eli-lilly-2020-05-22 | null | null | The COVID-19 pandemic has spared few companies, but AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) are two pharma giants whose businesses are thriving amid the ongoing crisis. Both drugmakers have also performed better than the broader market of late. Year to date, shares of AbbVie are up by 3.2%, while Eli Lilly's stoc... | Both AbbVie and Eli Lilly could continue to outperform the market moving forward, but which of these two pharma stocks is the better buy today? While I do believe the pharma giant remains a buy, I think Eli Lilly is the better pick right now because of AbbVie's significantly higher debt level. The COVID-19 pandemic has... | The COVID-19 pandemic has spared few companies, but AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) are two pharma giants whose businesses are thriving amid the ongoing crisis. After all, AbbVie's revenue of $8.6 billion during the first quarter -- and its non-GAAP earnings per share (EPS) of $2.42 -- compare favorably t... | Both AbbVie and Eli Lilly could continue to outperform the market moving forward, but which of these two pharma stocks is the better buy today? After all, AbbVie's revenue of $8.6 billion during the first quarter -- and its non-GAAP earnings per share (EPS) of $2.42 -- compare favorably to Eli Lilly's revenue of $5.9 b... | Year to date, shares of AbbVie are up by 3.2%, while Eli Lilly's stock is up by 17.8%. While I do believe the pharma giant remains a buy, I think Eli Lilly is the better pick right now because of AbbVie's significantly higher debt level. The COVID-19 pandemic has spared few companies, but AbbVie (NYSE: ABBV) and Eli Li... |
24,551 | 2020-05-22 00:00:00 UTC | Here's Why Editas Could Beat Intellia to a CRISPR Therapy | ABBV | https://www.nasdaq.com/articles/heres-why-editas-could-beat-intellia-to-a-crispr-therapy-2020-05-22 | null | null | Breakthrough genome editing companies including Editas (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) have been in a tailspin since late 2019, and the latest earnings reports from both of those companies show that their revenue from collaborations and partnerships has started to dry up despite positive revenue... | Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE: ABBV) and biopharma giant Bristol Myers Squibb (NYSE: BMY). There is one significant difference that wise investors will weigh carefully, however: Editas's partnerships and strategic collaborations appear positioned to be far mor... | Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE: ABBV) and biopharma giant Bristol Myers Squibb (NYSE: BMY). Breakthrough genome editing companies including Editas (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) have been in a tailspin since late 2019, and the latest ea... | Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE: ABBV) and biopharma giant Bristol Myers Squibb (NYSE: BMY). Breakthrough genome editing companies including Editas (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) have been in a tailspin since late 2019, and the latest ea... | Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE: ABBV) and biopharma giant Bristol Myers Squibb (NYSE: BMY). The expectation with these collaborations is that the more mature partner companies will be responsible for clinical-stage development, with Editas providing trial-ready... |
24,552 | 2020-05-21 00:00:00 UTC | Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results | ABBV | https://www.nasdaq.com/articles/galapagos-and-gilead-sciences-post-successful-yet-disappointing-filgotinib-results-2020-05 | null | null | Gilead Sciences (NASDAQ: GILD) and its collaboration partner, Galapagos (NASDAQ: GLPG), reported somewhat disappointing news for their anti-inflammatory candidate, filgotinib. The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbV... | Underwhelming data Ulcerative colitis patients who hadn't previously been treated with an injectable drug were significantly more likely to achieve remission with filgotinib than those given a placebo, but it looks like Gilead Sciences and Galapagos could have trouble competing with AbbVie for this population. The pote... | The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbVie (NYSE: ABBV) currently approved to treat patients with rheumatoid arthritis. Underwhelming data Ulcerative colitis patients who hadn't previously been treated with an inject... | The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbVie (NYSE: ABBV) currently approved to treat patients with rheumatoid arthritis. Underwhelming data Ulcerative colitis patients who hadn't previously been treated with an inject... | The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbVie (NYSE: ABBV) currently approved to treat patients with rheumatoid arthritis. Underwhelming data Ulcerative colitis patients who hadn't previously been treated with an inject... |
24,553 | 2020-05-21 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Akorn, L Brands, Aurora Cannabis | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-akorn-l-brands-aurora-cannabis-2020-05-21 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes dropped about 1% on Thursday as investors worried about escalating U.S.-China trade tensions and concerns over a quick rebound fr... | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 14.2% ** Norwegian Cruise Line Holdings Ltd , up 8.5% ** Royal Caribbean Cruises Ltd , up 6.5% The top three S&P 500 .PL.INX percentage losers: ** National-Oilwell Varco Inc , down 6.3% ** Boston Scientific Corp , down 5.8% ** Hormel Foods Corp , do... | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 14.2% ** Norwegian Cruise Line Holdings Ltd , up 8.5% ** Royal Caribbean Cruises Ltd , up 6.5% The top three S&P 500 .PL.INX percentage losers: ** National-Oilwell Varco Inc , down 6.3% ** Boston Scientific Corp , down 5.8% ** Hormel Foods Corp , do... | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 14.2% ** Norwegian Cruise Line Holdings Ltd , up 8.5% ** Royal Caribbean Cruises Ltd , up 6.5% The top three S&P 500 .PL.INX percentage losers: ** National-Oilwell Varco Inc , down 6.3% ** Boston Scientific Corp , down 5.8% ** Hormel Foods Corp , do... | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 14.2% ** Norwegian Cruise Line Holdings Ltd , up 8.5% ** Royal Caribbean Cruises Ltd , up 6.5% The top three S&P 500 .PL.INX percentage losers: ** National-Oilwell Varco Inc , down 6.3% ** Boston Scientific Corp , down 5.8% ** Hormel Foods Corp , do... |
24,554 | 2020-05-21 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2020-05-21 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on IBM — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Becton, Dickinson & Co (Symbol: BDX) $242.... | Becton, Dickinson & Co (Symbol: BDX) $242.99 $275.77 13.49% Johnson & Johnson (Symbol: JNJ) $147.68 $165.31 11.94% AptarGroup Inc. (Symbol: ATR) $104.41 $116.00 11.10% AbbVie Inc (Symbol: ABBV) $91.19 $100.64 10.36% International Business Machines Corp (Symbol: IBM) $121.38 $132.82 9.42% The average 12-month analyst ta... | Becton, Dickinson & Co (Symbol: BDX) $242.99 $275.77 13.49% Johnson & Johnson (Symbol: JNJ) $147.68 $165.31 11.94% AptarGroup Inc. (Symbol: ATR) $104.41 $116.00 11.10% AbbVie Inc (Symbol: ABBV) $91.19 $100.64 10.36% International Business Machines Corp (Symbol: IBM) $121.38 $132.82 9.42% The average 12-month analyst ta... | Becton, Dickinson & Co (Symbol: BDX) $242.99 $275.77 13.49% Johnson & Johnson (Symbol: JNJ) $147.68 $165.31 11.94% AptarGroup Inc. (Symbol: ATR) $104.41 $116.00 11.10% AbbVie Inc (Symbol: ABBV) $91.19 $100.64 10.36% International Business Machines Corp (Symbol: IBM) $121.38 $132.82 9.42% The average 12-month analyst ta... |
24,555 | 2020-05-21 00:00:00 UTC | Noteworthy ETF Inflows: MTUM, BMY, ABBV, VRTX | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-mtum-bmy-abbv-vrtx-2020-05-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $273.4 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (fro... | Among the largest underlying components of MTUM, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.3%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of... | Among the largest underlying components of MTUM, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.3%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.2%. For a complete list of holdings, visit the MTUM Holdings page » The chart below ... | Among the largest underlying components of MTUM, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.3%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of... | Among the largest underlying components of MTUM, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.3%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of... |
24,556 | 2020-05-19 00:00:00 UTC | AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions | ABBV | https://www.nasdaq.com/articles/abbvie-is-more-than-just-a-portfolio-of-drugs-and-acquisitions-2020-05-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Shares of AbbVie (NYSE:ABBV) are up nearly 10% since the company finalized its leveraged buyout of Allergan. The narrative surrounding the Allergan deal is that AbbVie needed to diversify its portfolio. Before you consider investing in ABBV stock, let’s che... | Speaking at the JPMorgan Chase Healthcare Conference, AbbVie CEO Rick Gonzalez pointed out that Skyrizi has already captured about 25% of the “in-play” market share. And according to David Risinger of Morgan Stanley, with Allergan in the fold, AbbVie has just 45% of its earnings at risk to expiring patents (and therefo... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE:ABBV) are up nearly 10% since the company finalized its leveraged buyout of Allergan. AbbVie Had a Strong Portfolio Without Allergan The leveraged buyout of Allergan adds diversity to AbbVie’s portfolio. The narrative surrounding the ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE:ABBV) are up nearly 10% since the company finalized its leveraged buyout of Allergan. AbbVie Had a Strong Portfolio Without Allergan The leveraged buyout of Allergan adds diversity to AbbVie’s portfolio. AbbVie Has a Strong Pipeline B... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE:ABBV) are up nearly 10% since the company finalized its leveraged buyout of Allergan. The narrative surrounding the Allergan deal is that AbbVie needed to diversify its portfolio. Before you consider investing in ABBV stock, let’s che... |
24,557 | 2020-05-17 00:00:00 UTC | Wall Street Week Ahead-Investors prepare for more U.S. stock swings as states reopen | ABBV | https://www.nasdaq.com/articles/wall-street-week-ahead-investors-prepare-for-more-u.s.-stock-swings-as-states-reopen-2020 | null | null | By April Joyner
NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise.
The Cboe Volatility Index .VIX, known as Wall Street's fear gauge, posted its biggest weekly gain in about two months, reflecting the S&... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. Hopes for a speedy return to normal took another hit when California's state university system canceled classes for the fall semester because of the coronavirus and Los Angeles County said its stay-at-home order was likel... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. Concerns over economic reopening are reflected in the VIX futures curve, which shows investors betting volatility will be elevated in coming weeks, rather than later in the summer, said Christopher Murphy, co-head of deri... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Concerns over economic reopening are ... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Many are watching progress of U.S. st... |
24,558 | 2020-05-15 00:00:00 UTC | Wall St Week Ahead-Investors prepare for more U.S. stock swings as states reopen | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-investors-prepare-for-more-u.s.-stock-swings-as-states-reopen-2020-05-0 | null | null | By April Joyner
NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise.
The Cboe Volatility Index .VIX, known as Wall Street's fear gauge, posted its biggest weekly gain in about two months, reflecting the S&... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. Hopes for a speedy return to normal took another hit when California's state university system canceled classes for the fall semester because of the coronavirus and Los Angeles County said its stay-at-home order was likel... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. Concerns over economic reopening are reflected in the VIX futures curve, which shows investors betting volatility will be elevated in coming weeks, rather than later in the summer, said Christopher Murphy, co-head of deri... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Concerns over economic reopening are ... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Many are watching progress of U.S. st... |
24,559 | 2020-05-15 00:00:00 UTC | Wall St Week Ahead-Investors prepare for more U.S. stock swings as states reopen | ABBV | https://www.nasdaq.com/articles/wall-st-week-ahead-investors-prepare-for-more-u.s.-stock-swings-as-states-reopen-2020-05 | null | null | By April Joyner
NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise.
The Cboe Volatility Index .VIX, known as Wall Street's fear gauge, is set for its biggest weekly gain in about two months, reflecting a ... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. Hopes for a speedy return to normal took another hit when California's state university system canceled classes for the fall semester because of the coronavirus and Los Angeles County said its stay-at-home order was likel... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Concerns over economic reopening are ... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Concerns over economic reopening are ... | His firm owns shares of Bristol-Myers Squibb Co BMY.N, AbbVie Inc ABBV.N and Merck & Co Inc MRK.N. By April Joyner NEW YORK, May 15 (Reuters) - Investors are bracing for more turbulence in U.S. stocks, as some states prepare to reopen their economies and global trade tensions rise. Some investors said they are likely t... |
24,560 | 2020-05-14 00:00:00 UTC | S&P 500 Analyst Moves: ABBV | ABBV | https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-abbv-2020-05-14 | null | null | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick, moving up by 10 spots.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those a... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick, moving up by 10 spots. Looking at the stock price movement year to date, AbbVie is showing a gain of 1.1%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opin... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick, moving up by 10 spots. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessaril... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick, moving up by 10 spots. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessaril... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick, moving up by 10 spots. Looking at the stock price movement year to date, AbbVie is showing a gain of 1.1%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opin... |
24,561 | 2020-05-14 00:00:00 UTC | Is Now a Good Time To Buy Neurocrine Biosciences? | ABBV | https://www.nasdaq.com/articles/is-now-a-good-time-to-buy-neurocrine-biosciences-2020-05-14 | null | null | Neurocrine Biosciences (NASDAQ: NBIX) had a big day Tuesday, the latest in a string of good days. Since the stock bottomed out at $75.11 almost two months ago, it climbed as high as $119.65 on Tuesday, a jump of 44.5%, though it closed at $112.60. This is a run that may continue, despite any short-term coronavirus head... | Neurocrine received $14.3 million last year from AbbVie in royalty payments related to Orilissa The company is expanding its pipeline and profits by partnering successfully with other companies, including gene therapy provider Voyager Therapeutics (NASDAQ: VYGR), biopharma Xenon Pharmaceuticals (NASDAQ: XENE), and Swis... | Neurocrine received $14.3 million last year from AbbVie in royalty payments related to Orilissa The company is expanding its pipeline and profits by partnering successfully with other companies, including gene therapy provider Voyager Therapeutics (NASDAQ: VYGR), biopharma Xenon Pharmaceuticals (NASDAQ: XENE), and Swis... | Neurocrine received $14.3 million last year from AbbVie in royalty payments related to Orilissa The company is expanding its pipeline and profits by partnering successfully with other companies, including gene therapy provider Voyager Therapeutics (NASDAQ: VYGR), biopharma Xenon Pharmaceuticals (NASDAQ: XENE), and Swis... | Neurocrine received $14.3 million last year from AbbVie in royalty payments related to Orilissa The company is expanding its pipeline and profits by partnering successfully with other companies, including gene therapy provider Voyager Therapeutics (NASDAQ: VYGR), biopharma Xenon Pharmaceuticals (NASDAQ: XENE), and Swis... |
24,562 | 2020-05-13 00:00:00 UTC | It’s Time to Buy AbbVie Stock Now After Its Allergan Purchase | ABBV | https://www.nasdaq.com/articles/its-time-to-buy-abbvie-stock-now-after-its-allergan-purchase-2020-05-13 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
On Friday, Allergan shares ceased trading as the company’s merger with AbbVie (NYSE:ABBV) finally went through. The deal removes AGN stock from the exchanges, and those who were long are now long AbbVie (and the combined company).
Source: Piotr Swat / Shutt... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Friday, Allergan shares ceased trading as the company’s merger with AbbVie (NYSE:ABBV) finally went through. The deal removes AGN stock from the exchanges, and those who were long are now long AbbVie (and the combined company). Source: Piotr Swat / Shutt... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Friday, Allergan shares ceased trading as the company’s merger with AbbVie (NYSE:ABBV) finally went through. Source: Piotr Swat / Shutterstock.com Specifically, those investors received $120.30 per share in cash, along with 0.866 shares of AbbVie stock f... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Friday, Allergan shares ceased trading as the company’s merger with AbbVie (NYSE:ABBV) finally went through. Source: Piotr Swat / Shutterstock.com Specifically, those investors received $120.30 per share in cash, along with 0.866 shares of AbbVie stock f... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Friday, Allergan shares ceased trading as the company’s merger with AbbVie (NYSE:ABBV) finally went through. The deal removes AGN stock from the exchanges, and those who were long are now long AbbVie (and the combined company). Source: Piotr Swat / Shutt... |
24,563 | 2020-05-13 00:00:00 UTC | 2 Value Stocks That Will Make You Richer in May | ABBV | https://www.nasdaq.com/articles/2-value-stocks-that-will-make-you-richer-in-may-2020-05-13 | null | null | For investors with spare cash on hand, market sell-offs such as this one can provide plenty of opportunities. Stocks with sky-high valuations may have finally fallen to a price where it is reasonable to buy, and stocks that were cheap beforehand may have declined further into a valuation level that defies all reason.
M... | A blue-chip pharmaceutical stock AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. Last year, sales of the drug amounted to $19.17 billion, or 58% of AbbVie's total revenue. Furthermore, AbbVie is expecting $1.7 billion in revenue this year for Skyrizi and Rinvoq. | A blue-chip pharmaceutical stock AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. Last year, sales of the drug amounted to $19.17 billion, or 58% of AbbVie's total revenue. Furthermore, AbbVie is expecting $1.7 billion in revenue this year for Skyrizi and Rinvoq. | A blue-chip pharmaceutical stock AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. Last year, sales of the drug amounted to $19.17 billion, or 58% of AbbVie's total revenue. Furthermore, AbbVie is expecting $1.7 billion in revenue this year for Skyrizi and Rinvoq. | Last year, sales of the drug amounted to $19.17 billion, or 58% of AbbVie's total revenue. A blue-chip pharmaceutical stock AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. Furthermore, AbbVie is expecting $1.7 billion in revenue this year for Skyrizi and Rinvoq. |
24,564 | 2020-05-13 00:00:00 UTC | With Castro-era biotech, Cuba seeks to compete in coronavirus treatment race | ABBV | https://www.nasdaq.com/articles/with-castro-era-biotech-cuba-seeks-to-compete-in-coronavirus-treatment-race-2020-05-13 | null | null | By Sarah Marsh
HAVANA, May 13 (Reuters) - Communist-run Cuba, laboring under a six-decade U.S. embargo, is betting a biotech sector begun by late revolutionary leader Fidel Castro can give the Caribbean island an edge in a global race to find effective treatments for the new coronavirus.
Cuba is especially touting an i... | It is developing its own version of AbbVie's ABBV.N Kaletra, an HIV therapy being tested in combination with other drugs, including interferon, against COVID-19. By Sarah Marsh HAVANA, May 13 (Reuters) - Communist-run Cuba, laboring under a six-decade U.S. embargo, is betting a biotech sector begun by late revolutionar... | It is developing its own version of AbbVie's ABBV.N Kaletra, an HIV therapy being tested in combination with other drugs, including interferon, against COVID-19. The island nation says it has been successful in treating the novel coronavirus at home and in China, and that 80 countries have already expressed an interest... | It is developing its own version of AbbVie's ABBV.N Kaletra, an HIV therapy being tested in combination with other drugs, including interferon, against COVID-19. Interferons have long been used internationally to treat dengue fever, cancer and hepatitis B and C. Studies during the SARS epidemic in 2003 suggested interf... | It is developing its own version of AbbVie's ABBV.N Kaletra, an HIV therapy being tested in combination with other drugs, including interferon, against COVID-19. It now produces most of the drugs used in Cuba as well as more than 300 products for export to more than 50 countries, including a therapeutic vaccine for lun... |
24,565 | 2020-05-13 00:00:00 UTC | Is AbbVie a Buy Now That the Allergan Deal Is Done? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-buy-now-that-the-allergan-deal-is-done-2020-05-13 | null | null | The wait is over. AbbVie's (NYSE: ABBV) acquisition of Allergan closed on May 8, nearly one year after the big drugmaker first announced its planned buyout in June 2019. There were a few bumps along the way, though.
Some criticized AbbVie's decision to purchase Allergan for $63 billion from the beginning. A coalition o... | With Botox, Vraylar, and other Allergan products joining Imbruvica and AbbVie's newer drugs, the stock appears poised to be a winner for more conservative long-term investors. AbbVie's (NYSE: ABBV) acquisition of Allergan closed on May 8, nearly one year after the big drugmaker first announced its planned buyout in Jun... | AbbVie hopes to add new approved indications for Rinvoq, Skyrizi, Imbruvica, and Venclexta with late-stage clinical studies under way for all of these drugs. With Botox, Vraylar, and other Allergan products joining Imbruvica and AbbVie's newer drugs, the stock appears poised to be a winner for more conservative long-te... | What Allergan brings to the table Thanks to its acquisition of Allergan, AbbVie now has more than 120 additional products in its lineup that combined generated more than $16 billion in sales last year. While Botox is the 800-pound gorilla that Allergan brought to the table, there are several other drugs that AbbVie now... | AbbVie's (NYSE: ABBV) acquisition of Allergan closed on May 8, nearly one year after the big drugmaker first announced its planned buyout in June 2019. What Allergan brings to the table Thanks to its acquisition of Allergan, AbbVie now has more than 120 additional products in its lineup that combined generated more tha... |
24,566 | 2020-05-12 00:00:00 UTC | The Dow Can't Hang On --- and REITs Are Getting Crushed | ABBV | https://www.nasdaq.com/articles/the-dow-cant-hang-on-and-reits-are-getting-crushed-2020-05-12 | null | null | Invulnerable ? For six days now, the Nasdaq Composite has closed higher on the day. That streak looks to be at risk, with the Nasdaq fluctuating between positive and negative territory. But nothing has been able to keep the tech-heavy index down for long. That’s thanks to Apple (AAPL) and other tech stocks and some hot... | AbbVie (ABBV) has risen 4% after JPMorgan raised its rating on the stock to Overweight from Neutral. “Seeing the most innovative companies lead the market higher isn’t exactly a bad thing, not at all,” he writes. “Seeing one or two sectors move in one direction while the others veer off course could be troublesome.” A ... | AbbVie (ABBV) has risen 4% after JPMorgan raised its rating on the stock to Overweight from Neutral. The Technology Select Sector SPDR ETF (XLK) has gain 4.7% so far in May, while the Health Care Select Sector SPDR ETF (XLV) has risen 1.7%. “Seeing the most innovative companies lead the market higher isn’t exactly a ba... | AbbVie (ABBV) has risen 4% after JPMorgan raised its rating on the stock to Overweight from Neutral. Those are the same stocks that have been doing the heavy lifting for the stock market, generally, and the Nasdaq, specifically. The Technology Select Sector SPDR ETF (XLK) has gain 4.7% so far in May, while the Health C... | AbbVie (ABBV) has risen 4% after JPMorgan raised its rating on the stock to Overweight from Neutral. For six days now, the Nasdaq Composite has closed higher on the day. Those are the same stocks that have been doing the heavy lifting for the stock market, generally, and the Nasdaq, specifically. |
24,567 | 2020-05-12 00:00:00 UTC | AbbVie Stock Has 15% Upside, J.P. Morgan Analyst Says | ABBV | https://www.nasdaq.com/articles/abbvie-stock-has-15-upside-j.p.-morgan-analyst-says-2020-05-12 | null | null | AbbVie closed its acquisition of Allergan on Friday, and J.P. Morgan, which had advised Allergan on the deal, is now free of the restrictions that had kept it from showing its love for AbbVie’s stock.
J.P. Morgan analyst Chris Schott on Tuesday raised his rating on AbbVie shares (ticker: ABBV) to Overweight from Neutra... | AbbVie’s “valuation remains at steep discount vs. Major Pharma peers and we see significant upside for shares from here,” Schott said in his note. Even if biosimilar competition takes half of Humira sales in the first 18 months after AbbVie loses U.S. market exclusivity, Schott sees the company’s earnings bottoming at ... | J.P. Morgan analyst Chris Schott on Tuesday raised his rating on AbbVie shares (ticker: ABBV) to Overweight from Neutral and named the drugmaker one of J.P. Morgan’s top ideas. In early Tuesday trading, AbbVie shares were up 3%, to $90.80. Even if biosimilar competition takes half of Humira sales in the first 18 months... | AbbVie closed its acquisition of Allergan on Friday, and J.P. Morgan, which had advised Allergan on the deal, is now free of the restrictions that had kept it from showing its love for AbbVie’s stock. J.P. Morgan analyst Chris Schott on Tuesday raised his rating on AbbVie shares (ticker: ABBV) to Overweight from Neutra... | The market values AbbVie stock at only 8.5-times this year’s earnings forecast. Even if biosimilar competition takes half of Humira sales in the first 18 months after AbbVie loses U.S. market exclusivity, Schott sees the company’s earnings bottoming at $11 a share (compared with about $10 this year). AbbVie closed its ... |
24,568 | 2020-05-11 00:00:00 UTC | The Dow Slipped 109 Points Because Reopened Economies Aren't Business as Usual | ABBV | https://www.nasdaq.com/articles/the-dow-slipped-109-points-because-reopened-economies-arent-business-as-usual-2020-05-11 | null | null | As investors cautiously observed the impact of a reopening global economy, U.S. stocks pared back early losses on Monday to finish the session near the break-even line. The Dow Jones Industrial Average slipped 109.33 points, or 0.45%, to close at 24,221.99. The S&P 500 edged up 0.39 points, or 0.01%, to end at 2930.19,... | AbbVie stock (ticker: ABBV) jumped 4.6% on Monday after the drug giant completed its purchase of Botox maker Allergan. As investors cautiously observed the impact of a reopening global economy, U.S. stocks pared back early losses on Monday to finish the session near the break-even line. The lifted restrictions on busin... | AbbVie stock (ticker: ABBV) jumped 4.6% on Monday after the drug giant completed its purchase of Botox maker Allergan. South Korea quickly restored some social-distancing measures in Seoul and President Moon Jae-in warned in a national address that a second wave of infections could arise anytime and anywhere. Likewise,... | AbbVie stock (ticker: ABBV) jumped 4.6% on Monday after the drug giant completed its purchase of Botox maker Allergan. As investors cautiously observed the impact of a reopening global economy, U.S. stocks pared back early losses on Monday to finish the session near the break-even line. The lifted restrictions on busin... | AbbVie stock (ticker: ABBV) jumped 4.6% on Monday after the drug giant completed its purchase of Botox maker Allergan. The lifted restrictions on business operations and social distancing have raised both hopes and fears—hopes that economic activities would see a quick rebound, and fears of an uptick in coronavirus cas... |
24,569 | 2020-05-11 00:00:00 UTC | 5 Healthcare Stocks That Are Profitable but Also Cheap | ABBV | https://www.nasdaq.com/articles/5-healthcare-stocks-that-are-profitable-but-also-cheap-2020-05-11 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Today, keeping safe amid the novel coronavirus crisis is a priority for many people as they are restricted to home. That said, investing in solid healthcare stocks is perhaps one way to reinforce that priority.
I wanted to find cheap, but sturdy healthcare ... | Moreover, AbbVie’s $63 billion purchase of Allergan — expected to close shortly — will boost earnings and dividends and push ABBV stock higher. 7 of the Best Consumer Stocks to Buy Right Now So, here are the five healthcare stocks that have low P/E ratios and ample yields: CVS Health (NYSE:CVS) Walgreens Boots Alliance... | 7 of the Best Consumer Stocks to Buy Right Now So, here are the five healthcare stocks that have low P/E ratios and ample yields: CVS Health (NYSE:CVS) Walgreens Boots Alliance (NASDAQ:WBA) AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Cardinal Health (NYSE:CAH) With all of that in mind, let’s dive in. AbbVie (ABB... | 7 of the Best Consumer Stocks to Buy Right Now So, here are the five healthcare stocks that have low P/E ratios and ample yields: CVS Health (NYSE:CVS) Walgreens Boots Alliance (NASDAQ:WBA) AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Cardinal Health (NYSE:CAH) With all of that in mind, let’s dive in. AbbVie (ABB... | 7 of the Best Consumer Stocks to Buy Right Now So, here are the five healthcare stocks that have low P/E ratios and ample yields: CVS Health (NYSE:CVS) Walgreens Boots Alliance (NASDAQ:WBA) AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) Cardinal Health (NYSE:CAH) With all of that in mind, let’s dive in. AbbVie (ABB... |
24,570 | 2020-05-10 00:00:00 UTC | AbbVie Stock: Love It or Leave It? | ABBV | https://www.nasdaq.com/articles/abbvie-stock%3A-love-it-or-leave-it-2020-05-10 | null | null | The COVID-19 pandemic is still far from over, and many investors are increasingly looking for stability in a highly volatile stock market. And while no industry has been entirely immune to the adverse effects of the outbreak, some pharmaceutical companies have managed to handle the ongoing crisis better than most. AbbV... | It is worth noting that although AbbVie will pay approximately $41 billion in cash to fund this acquisition, the company significantly increased the amount of debt on its balance sheet. But AbbVie's long-term prospects also remain appealing, and in my view, the company's stock will continue to perform well long after t... | It is worth noting that although AbbVie will pay approximately $41 billion in cash to fund this acquisition, the company significantly increased the amount of debt on its balance sheet. AbbVie is particularly counting on Allergan's crown jewel, Botox, to decrease its reliance on Humira and generate strong cash flows. A... | Still, detractors may point to the fact that AbbVie's most important cash cow, Humira, continues to lose steam abroad: During the first quarter, Humira's international revenue was $1.047 billion, representing a 14.9% year-over-year decrease. AbbVie's juicy dividend Lastly, AbbVie remains a stock worth serious considera... | AbbVie (NYSE: ABBV) is one of those companies with financial results that haven't been hit hard by the public health crisis. It is worth noting that although AbbVie will pay approximately $41 billion in cash to fund this acquisition, the company significantly increased the amount of debt on its balance sheet. AbbVie's ... |
24,571 | 2020-05-10 00:00:00 UTC | What Investors Are Missing About Gilead Sciences | ABBV | https://www.nasdaq.com/articles/what-investors-are-missing-about-gilead-sciences-2020-05-10 | null | null | Gilead Sciences (NASDAQ: GILD) is quite the famous pharmaceutical company these days. Its antiviral remdesivir is the hot drug of the moment due to its apparent success in clinical trials with patients who have COVID-19, the disease caused by the SARS-CoV-2 coronavirus.
A hot drug leads to a lot of interest in a stock,... | Its 2013 spinoff, AbbVie (NYSE: ABBV) inherited a place in that celebrated group of stocks and has kept it by raising the distribution on the regular (it's also still the big rheumatoid arthritis player with its Humira). Gilead's 3.5% yield is close to the midpoint of Abbott Labs' 1.6% and AbbVie's 5.5%. But in my opin... | Its 2013 spinoff, AbbVie (NYSE: ABBV) inherited a place in that celebrated group of stocks and has kept it by raising the distribution on the regular (it's also still the big rheumatoid arthritis player with its Humira). Gilead's 3.5% yield is close to the midpoint of Abbott Labs' 1.6% and AbbVie's 5.5%. But in my opin... | Its 2013 spinoff, AbbVie (NYSE: ABBV) inherited a place in that celebrated group of stocks and has kept it by raising the distribution on the regular (it's also still the big rheumatoid arthritis player with its Humira). Gilead's 3.5% yield is close to the midpoint of Abbott Labs' 1.6% and AbbVie's 5.5%. But in my opin... | But in my opinion, Gilead has explosive potential immediately in front of it, more so than Abbott Labs, AbbVie, or numerous other dividend payers in Big Pharmaville. Its 2013 spinoff, AbbVie (NYSE: ABBV) inherited a place in that celebrated group of stocks and has kept it by raising the distribution on the regular (it'... |
24,572 | 2020-05-09 00:00:00 UTC | 3 Best Healthcare Stocks to Buy in May | ABBV | https://www.nasdaq.com/articles/3-best-healthcare-stocks-to-buy-in-may-2020-05-09 | null | null | The COVID-19 pandemic has wrecked havoc on several major industries this year. However, the healthcare sector has been one of the few bright spots in this rather ugly market. A wide swath of the healthcare space, in fact, is in positive territory for the year right now.
Generally speaking, investors have flocked to th... | Secondly, AbbVie's brand-new immunology medicines Skyrizi and Rinvoq, and its blood cancer franchise consisting of Imbruvica and Venclexta, are all exceeding expectations at the moment. AbbVie (NYSE: ABBV), Adverum Biotechnologies (NASDAQ: ADVM), and Heron Therapeutics (NASDAQ: HRTX) are three names healthcare investor... | AbbVie (NYSE: ABBV), Adverum Biotechnologies (NASDAQ: ADVM), and Heron Therapeutics (NASDAQ: HRTX) are three names healthcare investors will definitely want to keep their eyes on this month. AbbVie: A de-risked growth and income play AbbVie is a large-cap biopharma company. First and foremost, AbbVie is slated to close... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of April 16, 2020 George Budwell owns shares of AbbVie. AbbVie (NYSE: ABBV), Adverum Biotechnologies (NASDAQ: ADVM), and Heron Therapeutics (NASDAQ: HRTX... | AbbVie (NYSE: ABBV), Adverum Biotechnologies (NASDAQ: ADVM), and Heron Therapeutics (NASDAQ: HRTX) are three names healthcare investors will definitely want to keep their eyes on this month. AbbVie: A de-risked growth and income play AbbVie is a large-cap biopharma company. First and foremost, AbbVie is slated to close... |
24,573 | 2020-05-08 00:00:00 UTC | Is Gilead Sciences Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-2020-05-08 | null | null | Biotech giant Gilead Sciences (NASDAQ: GILD) has attracted widespread attention in recent weeks as its antiviral drug remdesivir gained momentum as a candidate for treating severe cases of COVID-19. Last week, remdesivir received authorization from the U.S. Food and Drug Administration (FDA) for use in severe cases of ... | There are at least 10 clinical trials getting under way comparing remdesivir to other antivirals, including drugs that are already in the marketplace and sold by industry heavyweights such as Eli Lilly and AbbVie. The drug is submitted for rheumatoid arthritis, but it's also in phase 3 trials for ulcerative colitis, Cr... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Crumly owns shares of AbbVie and Gilead Sciences. There are at least 10 clinical trials getting under way comparing remdesivir to other antivirals, including drugs that are already in the marketplace and sold by industry heavyweights such as Eli Lilly an... | There are at least 10 clinical trials getting under way comparing remdesivir to other antivirals, including drugs that are already in the marketplace and sold by industry heavyweights such as Eli Lilly and AbbVie. The drug is submitted for rheumatoid arthritis, but it's also in phase 3 trials for ulcerative colitis, Cr... | There are at least 10 clinical trials getting under way comparing remdesivir to other antivirals, including drugs that are already in the marketplace and sold by industry heavyweights such as Eli Lilly and AbbVie. The drug is submitted for rheumatoid arthritis, but it's also in phase 3 trials for ulcerative colitis, Cr... |
24,574 | 2020-05-06 00:00:00 UTC | 3 Dividend Stocks Perfect for Retirees | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-perfect-for-retirees-2020-05-06 | null | null | Dividend stocks are a perfect fit for a retiree's portfolio considering the supplemental income they provide, which also adds to investor returns in the long run as compounding works its magic.
However, not all dividend stocks are ideal for retirees. In retirement, it's ideal to own stocks that don't just pay out stabl... | This top healthcare stock won't disappoint you AbbVie (NYSE: ABBV) is a great choice for retirees for two big reasons: Its incredible dividend track record and clout in healthcare, another defensive sector. AbbVie is a pretty young company in the sense that it was formed in 2013 after separating from Abbott Laboratorie... | This top healthcare stock won't disappoint you AbbVie (NYSE: ABBV) is a great choice for retirees for two big reasons: Its incredible dividend track record and clout in healthcare, another defensive sector. AbbVie is a pretty young company in the sense that it was formed in 2013 after separating from Abbott Laboratorie... | This top healthcare stock won't disappoint you AbbVie (NYSE: ABBV) is a great choice for retirees for two big reasons: Its incredible dividend track record and clout in healthcare, another defensive sector. AbbVie is a pretty young company in the sense that it was formed in 2013 after separating from Abbott Laboratorie... | This top healthcare stock won't disappoint you AbbVie (NYSE: ABBV) is a great choice for retirees for two big reasons: Its incredible dividend track record and clout in healthcare, another defensive sector. AbbVie is a pretty young company in the sense that it was formed in 2013 after separating from Abbott Laboratorie... |
24,575 | 2020-05-06 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-GM, Axcella, Beyond Meat, SmileDirect | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gm-axcella-beyond-meat-smiledirect-2020-05-06 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and Nasdaq rose on Wednesday on hopes of a pickup in business activity as U.S. states eased coronavirus-induced curbs, with investors also looki... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc FLIR.O, up 9.9% ** Davita Inc DVA.N, up 7.1% ** Kla Corp KLAC.O, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corp OXY.N, down 9.2% ** Simon Property Group Inc SPG.N, down 7.7% ** Cincinnati Financial Corp CINF.O, ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc FLIR.O, up 9.9% ** Davita Inc DVA.N, up 7.1% ** Kla Corp KLAC.O, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corp OXY.N, down 9.2% ** Simon Property Group Inc SPG.N, down 7.7% ** Cincinnati Financial Corp CINF.O, ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc FLIR.O, up 9.9% ** Davita Inc DVA.N, up 7.1% ** Kla Corp KLAC.O, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corp OXY.N, down 9.2% ** Simon Property Group Inc SPG.N, down 7.7% ** Cincinnati Financial Corp CINF.O, ... | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc FLIR.O, up 9.9% ** Davita Inc DVA.N, up 7.1% ** Kla Corp KLAC.O, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corp OXY.N, down 9.2% ** Simon Property Group Inc SPG.N, down 7.7% ** Cincinnati Financial Corp CINF.O, ... |
24,576 | 2020-05-06 00:00:00 UTC | Salesforce.com To Replace Allergan In S&P100 | ABBV | https://www.nasdaq.com/articles/salesforce.com-to-replace-allergan-in-sp100-2020-05-06 | null | null | (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. DexCom Inc. (DXCM) will replace Allergan plc (AGN) in the S&P 500.
S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final ... | S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final conditions. (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. S&P Dow Jones Indices will make the changes effective p... | S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final conditions. (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. S&P MidCap 400 constituent Domino's Pizza Inc. (DPZ) wi... | S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final conditions. (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. S&P MidCap 400 constituent Domino's Pizza Inc. (DPZ) wi... | S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final conditions. (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. DexCom Inc. (DXCM) will replace Allergan plc (AGN) in t... |
24,577 | 2020-05-05 00:00:00 UTC | AbbVie wins U.S. antitrust approval to buy Allergan | ABBV | https://www.nasdaq.com/articles/abbvie-wins-u.s.-antitrust-approval-to-buy-allergan-2020-05-05-0 | null | null | Adds details on deal, asset sales
WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie Inc ABBV.N has won U.S. antitrust approval to buy Botox maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday.
AbbVie, which has been under pressure to diversify its portfolio, ... | Adds details on deal, asset sales WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie Inc ABBV.N has won U.S. antitrust approval to buy Botox maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, ... | Adds details on deal, asset sales WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie Inc ABBV.N has won U.S. antitrust approval to buy Botox maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, ... | Adds details on deal, asset sales WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie Inc ABBV.N has won U.S. antitrust approval to buy Botox maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, ... | Adds details on deal, asset sales WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie Inc ABBV.N has won U.S. antitrust approval to buy Botox maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, ... |
24,578 | 2020-05-05 00:00:00 UTC | AbbVie wins U.S. antitrust approval to buy Allergan | ABBV | https://www.nasdaq.com/articles/abbvie-wins-u.s.-antitrust-approval-to-buy-allergan-2020-05-05 | null | null | WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie ABBV.N has won U.S. antitrust approval to buy Botox-maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday.
To win the approval from the Federal Trade Commission, the companies said they agreed to divest bra... | WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie ABBV.N has won U.S. antitrust approval to buy Botox-maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, said in June 2019 that it would a... | WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie ABBV.N has won U.S. antitrust approval to buy Botox-maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, said in June 2019 that it would a... | WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie ABBV.N has won U.S. antitrust approval to buy Botox-maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, said in June 2019 that it would a... | WASHINGTON, May 5 (Reuters) - Drugmaker AbbVie ABBV.N has won U.S. antitrust approval to buy Botox-maker Allergan AGN.N, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, said in June 2019 that it would a... |
24,579 | 2020-05-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Airlines, banks, oil stocks, Co-Diagnostics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-airlines-banks-oil-stocks-co-diagnostics-2020-05-04 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock index futures retreated on Monday after a fresh spat between Washington and Beijing over the origin of the novel coronavirus, while airlines slum... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc QES.N, up 15.7% ** ASE Technology Holding Co Ltd ASX.N, up 11.5% ** Pennsylvania Real Estate Investment Trust PEI.N, up 8.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Flagstar Bancorp Inc FBC.N, down 13.5% ** TET... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc QES.N, up 15.7% ** ASE Technology Holding Co Ltd ASX.N, up 11.5% ** Pennsylvania Real Estate Investment Trust PEI.N, up 8.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Flagstar Bancorp Inc FBC.N, down 13.5% ** TET... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc QES.N, up 15.7% ** ASE Technology Holding Co Ltd ASX.N, up 11.5% ** Pennsylvania Real Estate Investment Trust PEI.N, up 8.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Flagstar Bancorp Inc FBC.N, down 13.5% ** TET... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc QES.N, up 15.7% ** ASE Technology Holding Co Ltd ASX.N, up 11.5% ** Pennsylvania Real Estate Investment Trust PEI.N, up 8.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Flagstar Bancorp Inc FBC.N, down 13.5% ** TET... |
24,580 | 2020-05-02 00:00:00 UTC | The 3 Most Important Things to Know About AbbVie's Q1 Update | ABBV | https://www.nasdaq.com/articles/the-3-most-important-things-to-know-about-abbvies-q1-update-2020-05-02 | null | null | AbbVie's (NYSE: ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. But its underlying business hasn't.
The big drugmaker announced its first-quarter results before the market opened on Friday. AbbVie easily beat Wall Street's revenue and earnings estimates, delivering strong year-over-year g... | AbbVie easily beat Wall Street's revenue and earnings estimates, delivering strong year-over-year growth on its top and bottom lines. AbbVie's (NYSE: ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. But here are the three most important things to know about AbbVie's Q1 update. | Assuming all goes as planned, AbbVie's next quarterly update will include sales from Allergan's blockbuster Botox franchise, fast-rising star Vraylar, and more. AbbVie's (NYSE: ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. AbbVie easily beat Wall Street's revenue and earnings estimates,... | AbbVie reported total Q1 sales for the drug of $4.7 billion, up 5.8% year over year. First-quarter sales for AbbVie's blood cancer franchise soared 32.1% year over year. Humira will still be a major contributor to AbbVie, but after the second quarter, the immunology drug will no longer generate more than half of the co... | If those assumptions don't pan out, COVID-19 could be a much more important factor in AbbVie's quarterly updates later this year. AbbVie's (NYSE: ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. AbbVie easily beat Wall Street's revenue and earnings estimates, delivering strong year-over-ye... |
24,581 | 2020-05-01 00:00:00 UTC | Health Care Sector Update for 05/01/2020: HRC, SEM, ABBV, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-05-01-2020%3A-hrc-sem-abbv-xlv-ibb-2020-05-01 | null | null | Health care stocks were retreating pre-bell Friday, with both the Health Care SPDR (XLV) and the iShares NASDAQ Biotechnology Index (IBB) down more than 1%.
Hill-Rom Holdings Inc (HRC) was declining more than 6% as it reported a Q2 fiscal 2020 adjusted diluted EPS of $1.28, compared with $1.14 during the year-ago quart... | AbbVie (ABBV) was slightly lower as it reported Q1 adjusted diluted earnings of $2.42 per share, up from $2.14 per share a year ago. Hill-Rom Holdings Inc (HRC) was declining more than 6% as it reported a Q2 fiscal 2020 adjusted diluted EPS of $1.28, compared with $1.14 during the year-ago quarter. Select Medical Holdi... | AbbVie (ABBV) was slightly lower as it reported Q1 adjusted diluted earnings of $2.42 per share, up from $2.14 per share a year ago. Analysts polled by Capital IQ had projected EPS of $0.32 and revenue of $1.36 billion for the quarter. Net revenue rose to $8.62 billion from $7.83 billion a year ago, according to a stat... | AbbVie (ABBV) was slightly lower as it reported Q1 adjusted diluted earnings of $2.42 per share, up from $2.14 per share a year ago. Net operating revenue was $1.41 billion, compared with $1.32 billion in the same quarter last year. Analysts polled by Capital IQ had projected EPS of $0.32 and revenue of $1.36 billion f... | AbbVie (ABBV) was slightly lower as it reported Q1 adjusted diluted earnings of $2.42 per share, up from $2.14 per share a year ago. Hill-Rom Holdings Inc (HRC) was declining more than 6% as it reported a Q2 fiscal 2020 adjusted diluted EPS of $1.28, compared with $1.14 during the year-ago quarter. Analysts polled by C... |
24,582 | 2020-05-01 00:00:00 UTC | AbbVie Q1 20 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q1-20-earnings-conference-call-at-9%3A00-am-et-2020-05-01 | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on May 1, 2020, to discuss Q1 20 earnings results.
To access the live webcast, log on to investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on May 1, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on May 1, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on May 1, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on May 1, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to investors.abbvie.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
24,583 | 2020-05-01 00:00:00 UTC | AbbVie Inc (ABBV) Q1 2020 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q1-2020-earnings-call-transcript-2020-05-01 | null | null | Image source: The Motley Fool.
AbbVie Inc (NYSE: ABBV)
Q1 2020 Earnings Call
May 1, 2020, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2020 Earnings Conference Call. [Operator I... | However, based on our analysis of the situation as well as reasonable timing assumptions for the return to a more normalized environment, we are confident in maintaining our full year adjusted earnings guidance, which speaks volumes about the strength of AbbVie's business momentum entering the COVID crisis. AbbVie Inc ... | Operator [Operator Closing Remarks] Duration: 79 minutes Call participants: Liz Shea -- Vice President, Investor Relations Richard A. Gonzalez -- Chairman of the Board and Chief Executive Officer Michael E. Severino -- Vice Chairman and President Robert A. Michael -- Executive Vice President, Chief Financial Officer Va... | Adjusting for COVID inventory dynamics, AbbVie's first quarter underlying operational sales growth was roughly 8.3%, significantly above expectations with double-digit underlying performance in both HemOnc and immunology, demonstrating the strong underlying performance of our business. Operator [Operator Closing Remark... | Operator [Operator Closing Remarks] Duration: 79 minutes Call participants: Liz Shea -- Vice President, Investor Relations Richard A. Gonzalez -- Chairman of the Board and Chief Executive Officer Michael E. Severino -- Vice Chairman and President Robert A. Michael -- Executive Vice President, Chief Financial Officer Va... |
24,584 | 2020-05-01 00:00:00 UTC | Friday's ETF with Unusual Volume: MDIV | ABBV | https://www.nasdaq.com/articles/fridays-etf-with-unusual-volume%3A-mdiv-2020-05-01 | null | null | The Multi-Asset Diversified Income Index Fund ETF is seeing unusually high volume in afternoon trading Friday, with over 2.3 million shares traded versus three month average volume of about 321,000. Shares of MDIV were down about 3.5% on the day.
Components of that ETF with the highest volume on Friday were Ford Motor,... | Abbvie is the component faring the best Friday, up by about 1.5% on the day, while Gaslog Partners is lagging other components of the Multi-Asset Diversified Income Index Fund ETF, trading lower by about 12.8%. The Multi-Asset Diversified Income Index Fund ETF is seeing unusually high volume in afternoon trading Friday... | Abbvie is the component faring the best Friday, up by about 1.5% on the day, while Gaslog Partners is lagging other components of the Multi-Asset Diversified Income Index Fund ETF, trading lower by about 12.8%. The Multi-Asset Diversified Income Index Fund ETF is seeing unusually high volume in afternoon trading Friday... | Abbvie is the component faring the best Friday, up by about 1.5% on the day, while Gaslog Partners is lagging other components of the Multi-Asset Diversified Income Index Fund ETF, trading lower by about 12.8%. The Multi-Asset Diversified Income Index Fund ETF is seeing unusually high volume in afternoon trading Friday... | Abbvie is the component faring the best Friday, up by about 1.5% on the day, while Gaslog Partners is lagging other components of the Multi-Asset Diversified Income Index Fund ETF, trading lower by about 12.8%. The Multi-Asset Diversified Income Index Fund ETF is seeing unusually high volume in afternoon trading Friday... |
24,585 | 2020-05-01 00:00:00 UTC | AbbVie Confirms Standalone 2020 Adj. EPS Guidance - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-confirms-standalone-2020-adj.-eps-guidance-quick-facts-2020-05-01 | null | null | (RTTNews) - AbbVie (ABBV) confirmed its previous guidance to deliver standalone adjusted earnings per share for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The standalone 2020 adjusted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash ... | (RTTNews) - AbbVie (ABBV) confirmed its previous guidance to deliver standalone adjusted earnings per share for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. First quarter adjusted earnings per share was $2.42 compared to $2.14, previous year. On average, 11 analysts polled b... | (RTTNews) - AbbVie (ABBV) confirmed its previous guidance to deliver standalone adjusted earnings per share for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The standalone 2020 adjusted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash ... | (RTTNews) - AbbVie (ABBV) confirmed its previous guidance to deliver standalone adjusted earnings per share for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The standalone 2020 adjusted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash ... | (RTTNews) - AbbVie (ABBV) confirmed its previous guidance to deliver standalone adjusted earnings per share for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The standalone 2020 adjusted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash ... |
24,586 | 2020-05-01 00:00:00 UTC | AbbVie Q1 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q1-adjusted-earnings-beat-estimates-2020-05-01 | null | null | (RTTNews) - AbbVie (ABBV) announced a profit for its first quarter that rose from last year.
The company's earnings totaled $3.01 billion, or $2.02 per share. This compares with $2.46 billion, or $1.65 per share, in last year's first quarter.
Excluding items, AbbVie reported adjusted earnings of $3.61 billion or $2.42 ... | (RTTNews) - AbbVie (ABBV) announced a profit for its first quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $3.61 billion or $2.42 per share for the period. AbbVie earnings at a glance: -Earnings (Q1): $3.61 Bln. | Excluding items, AbbVie reported adjusted earnings of $3.61 billion or $2.42 per share for the period. (RTTNews) - AbbVie (ABBV) announced a profit for its first quarter that rose from last year. AbbVie earnings at a glance: -Earnings (Q1): $3.61 Bln. | (RTTNews) - AbbVie (ABBV) announced a profit for its first quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $3.61 billion or $2.42 per share for the period. AbbVie earnings at a glance: -Earnings (Q1): $3.61 Bln. | AbbVie earnings at a glance: -Earnings (Q1): $3.61 Bln. (RTTNews) - AbbVie (ABBV) announced a profit for its first quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $3.61 billion or $2.42 per share for the period. |
24,587 | 2020-05-01 00:00:00 UTC | Abbvie quarterly sales beat as Humira shines; maintains forecast | ABBV | https://www.nasdaq.com/articles/abbvie-quarterly-sales-beat-as-humira-shines-maintains-forecast-2020-05-01 | null | null | May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly sales.
The forecast of $9.61 to $9.71 per share in earnings assumes that "stay-at-home" orders will be gr... | May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly sales. AbbVie said its total sales for the quarter ended March 31 were also slightly boosted by customers... | May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly sales. AbbVie's total sales rose 10.1% to $8.62 billion in the first quarter, beating analysts' estimates... | May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly sales. AbbVie's total sales rose 10.1% to $8.62 billion in the first quarter, beating analysts' estimates... | AbbVie's total sales rose 10.1% to $8.62 billion in the first quarter, beating analysts' estimates of $8.33 billion, according to IBES data from Refinitiv. May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira... |
24,588 | 2020-05-01 00:00:00 UTC | Abbvie stands by 2020 profit forecast as Humira fuels quarterly beat | ABBV | https://www.nasdaq.com/articles/abbvie-stands-by-2020-profit-forecast-as-humira-fuels-quarterly-beat-2020-05-01 | null | null | Adds share movement, background on other drugmakers' forecasts, compares profit with estimates
May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly profit and... | Adds share movement, background on other drugmakers' forecasts, compares profit with estimates May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly profit and... | Adds share movement, background on other drugmakers' forecasts, compares profit with estimates May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly profit and... | Adds share movement, background on other drugmakers' forecasts, compares profit with estimates May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly profit and... | AbbVie's total sales rose 10.1% to $8.62 billion in the first quarter, above analysts' estimates of $8.33 billion, according to IBES data from Refinitiv. Adds share movement, background on other drugmakers' forecasts, compares profit with estimates May 1 (Reuters) - AbbVie Inc ABBV.N stuck with its 2020 adjusted profit... |
24,589 | 2020-05-01 00:00:00 UTC | AbbVie Beats Q1 Estimates as U.S. Humira Sales Rise 13.7% | ABBV | https://www.nasdaq.com/articles/abbvie-beats-q1-estimates-as-u.s.-humira-sales-rise-13.7-2020-05-01 | null | null | AbbVie (NYSE: ABBV) reported its first-quarter results before the market opened on Friday, announcing revenue that rose 10.1% year over year to $8.62 billion. That result topped the average analysts' estimate of $8.33 billion. The giant drugmaker's adjusted diluted earnings were $2.42 per share, a solid increase from $... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie (NYSE: ABBV) reported its first-quarter results before the market opened on Friday, announcing revenue that rose 10.1% year over year to $8.62 billion. Humira still leading the... | AbbVie (NYSE: ABBV) reported its first-quarter results before the market opened on Friday, announcing revenue that rose 10.1% year over year to $8.62 billion. Humira still leading the way Sales of immunology drug Humira rose 5.8% year over year to $4.7 billion and accounted for nearly 55% of AbbVie's total revenue. Abb... | AbbVie (NYSE: ABBV) reported its first-quarter results before the market opened on Friday, announcing revenue that rose 10.1% year over year to $8.62 billion. Humira still leading the way Sales of immunology drug Humira rose 5.8% year over year to $4.7 billion and accounted for nearly 55% of AbbVie's total revenue. One... | AbbVie (NYSE: ABBV) reported its first-quarter results before the market opened on Friday, announcing revenue that rose 10.1% year over year to $8.62 billion. Humira still leading the way Sales of immunology drug Humira rose 5.8% year over year to $4.7 billion and accounted for nearly 55% of AbbVie's total revenue. Abb... |
24,590 | 2020-04-30 00:00:00 UTC | Strong Insider Buying Reported in DLN Holdings | ABBV | https://www.nasdaq.com/articles/strong-insider-buying-reported-in-dln-holdings-2020-04-30 | null | null | A look at the weighted underlying holdings of the WisdomTree U.S. LargeCap Dividend Fund (DLN) shows an impressive 26.0% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 1.63% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has se... | AbbVie Inc (Symbol: ABBV), which makes up 1.63% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $34,505,130 worth of ABBV, making it the #12 largest holding. The table below detai... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $83.76 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 1.63% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has seen 2 directors and officers purchase shares in the past six months, according to the re... | The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $83.76 — Recent Insider Buys: AbbVie Inc (Symbol: ABBV), which makes up 1.63% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has seen 2 directors and officers purchase shares in the past six months, according to the re... | AbbVie Inc (Symbol: ABBV), which makes up 1.63% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $34,505,130 worth of ABBV, making it the #12 largest holding. The table below detai... |
24,591 | 2020-04-29 00:00:00 UTC | 3 Healthcare Stocks With Solid Dividends to Hold Through Bumpy Times | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-with-solid-dividends-to-hold-through-bumpy-times-2020-04-29 | null | null | As the coronavirus pandemic continues, investors from every part of the spectrum are looking for safe, stable companies to rely on -- and a nice dividend doesn't hurt. Here are three great healthcare stocks whose dividends are the cherry on top of a great operation.
Start with Johnson & Johnson, the gold standard of h... | AbbVie is much more than Humira Pharmaceutical giant AbbVie (NYSE: ABBV) may only have been around since 2013, but that's not stopping it from making money: The company boasted 2019 full-year net revenue of $33.3 billion. But AbbVie has diversified its drug pipeline well beyond Humira, Two drugs, in particular, stand o... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Halley owns shares of AbbVie, GlaxoSmithKline, and Johnson & Johnson. AbbVie is much more than Humira Pharmaceutical giant AbbVie (NYSE: ABBV) may only have been around since 2013, but that's not stopping it from making money: The company boasted 2019 fu... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Halley owns shares of AbbVie, GlaxoSmithKline, and Johnson & Johnson. AbbVie is much more than Humira Pharmaceutical giant AbbVie (NYSE: ABBV) may only have been around since 2013, but that's not stopping it from making money: The company boasted 2019 fu... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Halley owns shares of AbbVie, GlaxoSmithKline, and Johnson & Johnson. AbbVie is much more than Humira Pharmaceutical giant AbbVie (NYSE: ABBV) may only have been around since 2013, but that's not stopping it from making money: The company boasted 2019 fu... |
24,592 | 2020-04-28 00:00:00 UTC | Buy Allergan Stock as Big Pharma’s Biggest Deal Is About to Close | ABBV | https://www.nasdaq.com/articles/buy-allergan-stock-as-big-pharmas-biggest-deal-is-about-to-close-2020-04-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Before the novel coronavirus took over pretty much all of the financial headlines, the pharmaceutical industry was buzzing about the takeover of Allergan (NYSE:AGN) by AbbVie (NYSE:ABBV). Since the spread of the virus, Allergan stock has slipped but recover... | AbbVie’s press release from June of 2019 summed up the synergistic value proposition succinctly and compellingly: “The success and scale of the combined commercial business ensures funding capacity and flexibility for simultaneous robust pipeline investment, debt reduction and capital return to shareholders. ROIC is ex... | Even with the takeover by AbbVie expected to take place in May, you can still buy Allergan stock shares with confidence. The combined companies generated $19 billion in operating cash flow in 2018.” A Great Deal at Just About Any Price At the time of the deal’s announcement, some financial gurus might have been amazed ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before the novel coronavirus took over pretty much all of the financial headlines, the pharmaceutical industry was buzzing about the takeover of Allergan (NYSE:AGN) by AbbVie (NYSE:ABBV). The combined companies generated $19 billion in operating cash flow i... | Even with the takeover by AbbVie expected to take place in May, you can still buy Allergan stock shares with confidence. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before the novel coronavirus took over pretty much all of the financial headlines, the pharmaceutical industry was buzzing about the tak... |
24,593 | 2020-04-28 00:00:00 UTC | 3 Dividend Stocks Yielding More Than 5% That Are Safe Buys Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-yielding-more-than-5-that-are-safe-buys-right-now-2020-04-28 | null | null | The higher a dividend yield is, the riskier the dividend is? This rule of thumb is applicable in many cases. Some stocks have really high dividend yields because there's an underlying problem that caused share prices to fall significantly. Those problems, at least in some cases, could eventually cause the dividends to ... | The company's internal research and development is also paying off nicely, with AbbVie launching two immunology drugs with blockbuster potential last year -- Rinvoq and Skyrizi. AbbVie AbbVie (NYSE: ABBV) currently offers a dividend yield of more than 5.6%. AbbVie has increased its dividend for 47 consecutive years. | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, and Brookfield Infrastructure Partners. AbbVie AbbVie (NYSE: ABBV) currently offers a dividend yield of more than 5.6%. AbbVie has increased its dividend for 47 consecutive years. | Like AbbVie, AT&T (NYSE: T) is a member of the Dividend Aristocrats club, an elite group of S&P 500 stocks that have raised their dividends for at least 25 years. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, and Brookfield Infrastructure ... | AbbVie has increased its dividend for 47 consecutive years. AbbVie AbbVie (NYSE: ABBV) currently offers a dividend yield of more than 5.6%. But isn't AbbVie a high risk with its top-selling drug Humira facing biosimilar competition in Europe with more biosimilar rivals on the way in the U.S. within the next three years... |
24,594 | 2020-04-28 00:00:00 UTC | The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors | ABBV | https://www.nasdaq.com/articles/the-abbvie-buyout-is-not-a-sure-thing-for-allergan-stock-investors-2020-04-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Prior to the novel coronavirus disrupting everything, pharmaceutical companies Allergan (NYSE:AGN) and AbbVie (NYSE:ABBV) enjoyed a strong start to the new year. As Barron’s Josh Nathan-Kazis pointed out, prior to the pandemic, AbbVie’s $63 billion acquisit... | As Barron’s Josh Nathan-Kazis pointed out, prior to the pandemic, AbbVie’s $63 billion acquisition of Botox-maker Allergan represented the biggest news in the sector. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prior to the novel coronavirus disrupting everything, pharmaceutical companies Allergan (N... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prior to the novel coronavirus disrupting everything, pharmaceutical companies Allergan (NYSE:AGN) and AbbVie (NYSE:ABBV) enjoyed a strong start to the new year. As Barron’s Josh Nathan-Kazis pointed out, prior to the pandemic, AbbVie’s $63 billion acquisit... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prior to the novel coronavirus disrupting everything, pharmaceutical companies Allergan (NYSE:AGN) and AbbVie (NYSE:ABBV) enjoyed a strong start to the new year. 30 Consumer Stocks to Buy Once the Coronavirus Pandemic Passes A Tailwind Gets Nasty for Allerg... | 30 Consumer Stocks to Buy Once the Coronavirus Pandemic Passes A Tailwind Gets Nasty for Allergan Stock According to Barron’s, an AbbVie spokesperson stated in March that the Allergan buyout will likely go ahead. This is also the reason why ABBV buying out Allergan stock is risky. InvestorPlace - Stock Market News, Sto... |
24,595 | 2020-04-27 00:00:00 UTC | Dr. Reddy's Labs Launches Fenofibrate Tablets In U.S. | ABBV | https://www.nasdaq.com/articles/dr.-reddys-labs-launches-fenofibrate-tablets-in-u.s.-2020-04-27 | null | null | (RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor (fenofibrate) Tablets, in the U.S. market.
The Fenofibrate Tablets are approved by the U.S. Food and Drug Administration.
Dr. Reddy's Fenofibrate Tablets USP, are av... | The company noted that AbbVie Inc.'s Tricor brand and generic had U.S. sales of approximately $90 million MAT for the twelve months ending in January 2020 according to IQVIA Health. (RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic v... | The company noted that AbbVie Inc.'s Tricor brand and generic had U.S. sales of approximately $90 million MAT for the twelve months ending in January 2020 according to IQVIA Health. (RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic v... | The company noted that AbbVie Inc.'s Tricor brand and generic had U.S. sales of approximately $90 million MAT for the twelve months ending in January 2020 according to IQVIA Health. (RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic v... | The company noted that AbbVie Inc.'s Tricor brand and generic had U.S. sales of approximately $90 million MAT for the twelve months ending in January 2020 according to IQVIA Health. (RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced Monday the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic v... |
24,596 | 2020-04-27 00:00:00 UTC | Analysts See 15% Gains Ahead For EQWL | ABBV | https://www.nasdaq.com/articles/analysts-see-15-gains-ahead-for-eqwl-2020-04-27 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 100 Equal Weight ET... | Invesco S&P 100 Equal Weight ETF EQWL $52.04 $59.90 15.10% AT&T Inc T $29.71 $35.47 19.39% Emerson Electric Co. EMR $53.82 $62.92 16.91% AbbVie Inc ABBV $83.59 $96.33 15.24% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underly... | Three of EQWL's underlying holdings with notable upside to their analyst target prices are AT&T Inc (Symbol: T), Emerson Electric Co. (Symbol: EMR), and AbbVie Inc (Symbol: ABBV). Similarly, EMR has 16.91% upside from the recent share price of $53.82 if the average analyst target price of $62.92/share is reached, and a... | Similarly, EMR has 16.91% upside from the recent share price of $53.82 if the average analyst target price of $62.92/share is reached, and analysts on average are expecting ABBV to reach a target price of $96.33/share, which is 15.24% above the recent price of $83.59. Three of EQWL's underlying holdings with notable up... | Invesco S&P 100 Equal Weight ETF EQWL $52.04 $59.90 15.10% AT&T Inc T $29.71 $35.47 19.39% Emerson Electric Co. EMR $53.82 $62.92 16.91% AbbVie Inc ABBV $83.59 $96.33 15.24% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underly... |
24,597 | 2020-04-27 00:00:00 UTC | Why You Can Buy AbbVie At a Massive Discount | ABBV | https://www.nasdaq.com/articles/why-you-can-buy-abbvie-at-a-massive-discount-2020-04-27 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Even though AbbVie’s (NYSE:ABBV) combo HIV drug does not benefit patients suffering from severe Covid-19, the company has an impending buyout of Allergan (NYSE:AGN) and strong growth ahead. But with a rich dividend yield of nearly 6% and a low price-earning... | But with a rich dividend yield of nearly 6% and a low price-earnings ratio, investors should expect steady growth for years to come from ABBV stock. The company said that “the better-than-expected launch trajectories of Skyrizi and Rinvoq and the continued strong performance of our hematological oncology franchise has ... | Opportunity with Allergan Acquisition AbbVie raised its expectations for Allergan after the company posted strong quarterly results. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even though AbbVie’s (NYSE:ABBV) combo HIV drug does not benefit patients suffering from severe Covid-19, the company has an... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even though AbbVie’s (NYSE:ABBV) combo HIV drug does not benefit patients suffering from severe Covid-19, the company has an impending buyout of Allergan (NYSE:AGN) and strong growth ahead. The company said that “the better-than-expected launch trajectories... | Opportunity with Allergan Acquisition AbbVie raised its expectations for Allergan after the company posted strong quarterly results. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even though AbbVie’s (NYSE:ABBV) combo HIV drug does not benefit patients suffering from severe Covid-19, the company has an... |
24,598 | 2020-04-26 00:00:00 UTC | Myovant Squares Off with AbbVie On Endometriosis Treatment | ABBV | https://www.nasdaq.com/articles/myovant-squares-off-with-abbvie-on-endometriosis-treatment-2020-04-26 | null | null | Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. The study evaluating relugolix as a treatment for pain caused by endometriosis met two co-primary endpoints and a slate of secondary endpoints. Relugolix has clearly pointed its ... | Myovant will be able to ride the coattails of AbbVie's efforts to raise awareness among doctors, payers, and patients on the need and value proposition for drugs like these. Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. Relu... | Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. Relugolix has clearly pointed its crosshairs on AbbVie's Orilissa, approved by the Food and Drug Administration (FDA) in 2018. Image Source: Getty Images High stakes AbbVie's Ori... | Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. Relugolix has clearly pointed its crosshairs on AbbVie's Orilissa, approved by the Food and Drug Administration (FDA) in 2018. Image Source: Getty Images High stakes AbbVie's Ori... | Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. Relugolix has clearly pointed its crosshairs on AbbVie's Orilissa, approved by the Food and Drug Administration (FDA) in 2018. Image Source: Getty Images High stakes AbbVie's Ori... |
24,599 | 2020-04-26 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2020-04-26 | null | null | More than 4,000 stocks that trade on U.S. stock exchanges pay dividends. Not all of them necessarily pay mouthwatering dividends, though. And many of them aren't ones that you'd want to buy.
However, there are some dividend stocks that I'd buy right now without hesitation. Here's why AbbVie (NYSE: ABBV), Brookfield Inf... | One reason why AbbVie is priced so low is that it faces biosimilar competition for its top-selling drug, Humira, in Europe with rivals scheduled to enter the U.S. market in 2023. Here's why AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Brookfield Renewable Partners (NYSE: BEP) are at the top ... | Here's why AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Brookfield Renewable Partners (NYSE: BEP) are at the top of my list. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partne... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. Here's why AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Brookfield Renewable Partners (NYSE: BEP) are at the top of m... | See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. Here's why AbbVie (NYSE: ABBV), Brookfield Infrastructure Partners (NYSE: BIP), and Brookfield Renewable Partners (NYSE: BEP) are at the top of m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.